


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T14:05:44Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12405446" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12405446</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>npjdigitmed</setSpec>
        
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">NPJ Digit Med</journal-id><journal-id journal-id-type="iso-abbrev">NPJ Digit Med</journal-id><journal-id journal-id-type="pmc-domain-id">3605</journal-id><journal-id journal-id-type="pmc-domain">npjdigitmed</journal-id><journal-title-group><journal-title>NPJ Digital Medicine</journal-title></journal-title-group><issn pub-type="epub">2398-6352</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12405446</article-id><article-id pub-id-type="pmcid-ver">PMC12405446.1</article-id><article-id pub-id-type="pmcaid">12405446</article-id><article-id pub-id-type="pmcaiid">12405446</article-id><article-id pub-id-type="pmid">40897851</article-id><article-id pub-id-type="doi">10.1038/s41746-025-01967-7</article-id><article-id pub-id-type="publisher-id">1967</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Machine learning analysis reveals tumor heterogeneity and stromal-immune niches in breast cancer</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Kuang</surname><given-names initials="J">Junjie</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Zhong</surname><given-names initials="G">Guofang</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Zhao</surname><given-names initials="L">Linfeng</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yuan</surname><given-names initials="X">Xia</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Zhou</surname><given-names initials="Y">Yundong</given-names></name><address><email>zyundongss@foxmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Li</surname><given-names initials="J">Jun</given-names></name><address><email>lijun_zlnk@163.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label>Cancer Center, Huizhou First Hospital, Huizhou, Guangdong China </aff><aff id="Aff2"><label>2</label>The Second Department of Cancer Center, Huizhou First Hospital, Huizhou, Guangdong China </aff></contrib-group><pub-date pub-type="epub"><day>2</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>8</volume><issue-id pub-id-type="pmc-issue-id">478273</issue-id><elocation-id>565</elocation-id><history><date date-type="received"><day>21</day><month>6</month><year>2025</year></date><date date-type="accepted"><day>18</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>02</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 00:25:59.930"><day>04</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="41746_2025_Article_1967.pdf"/><abstract id="Abs1"><p id="Par1">Breast cancer is a leading cause of cancer-related mortality, with tumor heterogeneity and drug resistance posing significant challenges to treatment. We integrated single-cell RNA sequencing, spatial transcriptomics, and bulk RNA-seq deconvolution to analyze BRCA samples. Our analysis identified 15 major cell clusters, including neoplastic epithelial, immune, stromal, and endothelial populations. Notably, low-grade tumors showed enriched subtypes, such as CXCR4+ fibroblasts, IGKC+ myeloid cells, and CLU+ endothelial cells, with distinct spatial localization and immune-modulatory functions. These subtypes were paradoxically linked to reduced immunotherapy responsiveness, despite their association with favorable clinical features. High-grade tumors exhibited reprogrammed intercellular communication, with expanded MDK and Galectin signaling. Bulk RNA-seq deconvolution further supported the prognostic significance of low-grade-enriched subtypes. Our findings highlight the heterogeneity of the tumor microenvironment and provide new insights into immune evasion and therapeutic resistance in breast cancer.</p></abstract><kwd-group kwd-group-type="npg-subject"><title>Subject terms</title><kwd>Breast cancer</kwd><kwd>Cancer microenvironment</kwd><kwd>Cancer therapy</kwd><kwd>Tumour immunology</kwd></kwd-group><funding-group><award-group><funding-source><institution>Research Cultivation and Innovation Fund of Huizhou First Hospital</institution></funding-source><award-id>2024QN001</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100021171</institution-id><institution>Basic and Applied Basic Research Foundation of Guangdong Province</institution></institution-wrap></funding-source><award-id>2023A1515140039</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution>Huizhou Science and Technology Research and Development Program</institution></funding-source><award-id>2024CZ010001</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer Nature Limited 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p id="Par2">Breast cancer (BRCA) remains the most prevalent and lethal malignancy affecting women worldwide. As of 2020, it accounted for approximately 2.3 million new cases and 685,000 deaths globally, representing 24.5% of all new cancer diagnoses and 15.5% of all cancer-related deaths among women<sup><xref ref-type="bibr" rid="CR1">1</xref></sup>. In the United States, BRCA has become the most commonly diagnosed cancer among women, with projections indicating it will constitute the largest number of new cancer cases across all types by 2023. It currently accounts for 31% of all female cancer diagnoses and ranks as the second leading cause of cancer-related mortality in women<sup><xref ref-type="bibr" rid="CR1">1</xref>,<xref ref-type="bibr" rid="CR2">2</xref></sup>. Clinically, breast cancer is stratified into distinct molecular subtypes&#8212;including Luminal A, Luminal B, HER2-enriched, and triple-negative&#8212;based on the expression patterns of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and the proliferation marker Ki-67. These classifications are critical for guiding treatment decisions, as they reflect the disease&#8217;s inherent heterogeneity and complexity&#8212;factors that continue to pose major challenges despite significant therapeutic advancements<sup><xref ref-type="bibr" rid="CR3">3</xref>&#8211;<xref ref-type="bibr" rid="CR6">6</xref></sup>. Current standard treatments consist of surgical resection, radiation therapy, and endocrine therapy, often combined with neoadjuvant chemotherapy and targeted agents in high-risk patients. However, issues such as therapy resistance, tumor recurrence, and distant metastasis remain substantial barriers to long-term disease control<sup><xref ref-type="bibr" rid="CR7">7</xref></sup>. In addition to therapeutic limitations, current diagnostic methodologies also exhibit notable shortcomings. Immunohistochemistry (IHC), although widely used for subtype classification, is limited by its invasiveness, interpretive variability, and suboptimal suitability for certain patient populations<sup><xref ref-type="bibr" rid="CR8">8</xref>,<xref ref-type="bibr" rid="CR9">9</xref></sup>. While gene expression profiling&#8212;such as PAM50-based intrinsic subtyping&#8212;offers enhanced molecular resolution, its clinical implementation is constrained by high costs and logistical hurdles<sup><xref ref-type="bibr" rid="CR9">9</xref></sup>. Nevertheless, several prognostic gene signatures have recently been introduced into clinical practice, offering potential to improve diagnostic accuracy, risk stratification, and personalized treatment planning<sup><xref ref-type="bibr" rid="CR10">10</xref>,<xref ref-type="bibr" rid="CR11">11</xref></sup>. These advances underscore the urgent need for robust and accessible biomarkers to enhance early detection and clinical management of BRCA, aiming to alleviate its global health burden.</p><p id="Par3">A growing body of evidence highlights the tumor microenvironment (TME) as a critical determinant of breast cancer progression, therapeutic resistance, and metastasis. The TME comprises a complex cellular milieu&#8212;including stromal, immune, and vascular cells&#8212;that is dynamically shaped by tumor-secreted cytokines, chemokines, and growth factors. These factors not only recruit surrounding cell populations but also reprogram their functions to promote a tumor-supportive niche<sup><xref ref-type="bibr" rid="CR3">3</xref>,<xref ref-type="bibr" rid="CR12">12</xref>,<xref ref-type="bibr" rid="CR13">13</xref></sup>. This intricate microenvironment modulates cancer behavior, alters drug responsiveness, and contributes to immune evasion.</p><p id="Par4">Among the various components of the TME, cancer-associated fibroblasts (CAFs) and tumor-associated neutrophils (TANs) play particularly pivotal roles. CAFs actively remodel the extracellular matrix, secrete pro-tumorigenic factors, and facilitate angiogenesis, thereby promoting tumor growth and metastatic potential<sup><xref ref-type="bibr" rid="CR14">14</xref></sup>. TANs exhibit functional plasticity and can polarize into either pro-inflammatory/anti-tumorigenic or anti-inflammatory/pro-tumorigenic phenotypes in response to the surrounding cytokine milieu. Their direct interactions with cancer cells can induce the expression of oncostatin M (OSM), which&#8212;despite its antiproliferative role in certain contexts&#8212;has been implicated in promoting angiogenesis and metastasis in BRCA<sup><xref ref-type="bibr" rid="CR15">15</xref>,<xref ref-type="bibr" rid="CR16">16</xref></sup>.</p><p id="Par5">Additionally, tumor-associated macrophages (TAMs) are strongly associated with poor prognosis and adverse clinical outcomes in breast cancer. TAMs support immune suppression, tumor growth, angiogenesis, and metastatic dissemination. Notably, they can also be recruited in response to chemotherapy, where they contribute to a pro-metastatic TME that undermines therapeutic efficacy<sup><xref ref-type="bibr" rid="CR17">17</xref>,<xref ref-type="bibr" rid="CR18">18</xref></sup>. These multifaceted interactions within the TME underscore the importance of developing therapeutic strategies that target not only tumor-intrinsic factors but also the supportive and adaptive components of the microenvironment.</p><p id="Par6">In this study, we systematically investigated the multicellular ecosystem of breast cancer using single-cell and spatial transcriptomics. Our aim was to delineate cellular heterogeneity within the TME, uncover regulatory interactions, and identify candidate biomarkers for improved diagnosis and early intervention in breast cancer.</p></sec><sec id="Sec2" sec-type="results"><title>Results</title><sec id="Sec3"><title>Comprehensive single-cell atlas reveals cellular composition of the brca tumor microenvironment</title><p id="Par7">To dissect the cellular heterogeneity of BRCA, we performed scRNA-seq analysis, followed by unsupervised clustering and dimensionality reduction. This revealed 15 transcriptionally distinct cell clusters (Fig. <xref rid="Fig1" ref-type="fig">1A</xref>), with UMAP visualization delineating clear separation among major cell types (Fig. <xref rid="Fig1" ref-type="fig">1B</xref>). Cluster annotation based on canonical marker genes identified neoplastic epithelial cells (EPCAM, KRT18, KRT19, CDH1), fibroblasts (DCN, THY1, COL1A1, COL1A2), endothelial cells (PECAM1, CLDN5, FLT1, RAMP2), T cells (CD3D, CD3E, CD3G, TRAC), NK cells (NKG7, GNLY, NCAM1, KLRD1), B cells (CD79A, IGHM, IGHG3, IGHA2), myeloid cells (LYZ, MARCO, CD68, FCGR3A), and mast cells (KIT, MS4A2, GATA2) (Fig. <xref rid="Fig1" ref-type="fig">1D</xref>). Dot plots confirmed distinct marker gene expression per cluster (Fig. <xref rid="Fig1" ref-type="fig">1C</xref>), validating the annotation. Additional analyses characterized tumor grade distribution (Fig. <xref rid="Fig1" ref-type="fig">1E</xref>), patient contribution to each cluster (Fig. <xref rid="Fig1" ref-type="fig">1F</xref>), cell abundance (Fig. <xref rid="Fig1" ref-type="fig">1G</xref>), and total transcript counts (Fig. <xref rid="Fig1" ref-type="fig">1H</xref>), collectively delineating the BRCA TME.<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><title>Single-cell transcriptomic landscape of BRCA tumor microenvironment.</title><p><bold>A</bold> UMAP plot showing unsupervised clustering of all single cells, identifying 15 transcriptionally distinct clusters. <bold>B</bold> UMAP visualization of annotated major cell types. <bold>C</bold> UMAP feature plots showing expression of representative marker genes. <bold>D</bold> Heatmap displaying scaled expression of selected canonical marker genes across identified cell clusters. <bold>E</bold> Tumor grade distribution across cell types. <bold>F</bold> Contribution of individual patients to each cluster. <bold>G</bold> Relative abundance of each cell type. <bold>H</bold> Total transcript counts per cell type.</p></caption><graphic id="d33e333" position="float" orientation="portrait" xlink:href="41746_2025_1967_Fig1_HTML.jpg"/></fig></p></sec><sec id="Sec4"><title>Stromal and myeloid subtypes exhibit distinct functional programs and grade-associated patterns</title><p id="Par8">To refine characterization of stromal and myeloid cells, we extracted endothelial cells, fibroblasts, and myeloid populations and performed secondary clustering, identifying eight endothelial, ten fibroblast, and ten myeloid subclusters (Fig. <xref rid="Fig2" ref-type="fig">2B&#8211;D</xref>). Marker gene analysis revealed functional diversity (Fig. <xref rid="Fig2" ref-type="fig">2E, F</xref>). Fibroblast subsets expressing MYH11 were annotated as vascular smooth muscle cells (VSMCs), while those enriched in PDGFRA were identified as CAFs. Functional enrichment analyses of fibroblast subtypes revealed distinct biological roles (Fig. <xref rid="Fig2" ref-type="fig">2G&#8211;J</xref>). Notably, CAFs were enriched in low-grade tumors, implicating their involvement in early tumorigenesis (Fig. <xref rid="Fig2" ref-type="fig">2K, L</xref>).<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><title>Stromal and myeloid subpopulations exhibit functional heterogeneity and tumor-grade-specific patterns.</title><p><bold>A</bold> UMAP visualization of annotated major cell types. <bold>B&#8211;D</bold> UMAP plots of endothelial, fibroblast, and myeloid subclusters. <bold>E</bold>, <bold>F</bold> UMAP feature plots of representative marker genes per subcluster. <bold>G</bold> Feature plots showing expression of MYH11 and PDGFRA, used to identify VSMC and CAF, respectively. <bold>H</bold> Heatmap of functional enrichment scores for the ten fibroblast subclusters. <bold>I</bold> UMAP plot highlighting CAFs, pericytes, and VSMCs among the fibroblast compartment. <bold>J</bold> Bar plots of functional enrichment terms for highly variable genes in CAF and VSMC subclusters. <bold>K</bold> Proportional distribution of the ten fibroblast subclusters across low-, intermediate-, and high-grade tumors. <bold>L</bold> Tumor grade-specific abundance of CAFs, pericytes, and VSMCs visualized as grouped bar plots.</p></caption><graphic id="d33e388" position="float" orientation="portrait" xlink:href="41746_2025_1967_Fig2_HTML.jpg"/></fig></p></sec><sec id="Sec5"><title>Spatial transcriptomics uncovers region-specific cell distribution and tumor-grade associations</title><p id="Par9">We integrated spatial transcriptomic data from nine BRCA samples. CNV inference and cell-type deconvolution via inferCNV and CARD enabled tumor/non-tumor classification. A comprehensive spatial panel was generated for each sample, including H&amp;E staining, CNV scores, cell-type composition, and cluster maps (Fig. <xref rid="Fig3" ref-type="fig">3A</xref>). Tumor and non-tumor cells formed five and three transcriptional subtypes, respectively (Fig. <xref rid="Fig3" ref-type="fig">3B&#8211;E</xref>), each with unique CNV and marker gene signatures. Spatial mapping showed tumor- and immune-enriched zones, with high-grade tumors displaying greater tumor cell density and intermediate-grade tumors showing higher immune cell content (Fig. <xref rid="Fig3" ref-type="fig">3F, G</xref>).<fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><title>Spatial transcriptomic analysis reveals region-specific cell distributions and tumor-grade-associated patterns.</title><p><bold>A</bold> Overview of spatial transcriptomics workflow integrating H&amp;E imaging, CNV inference, and cell type deconvolution. <bold>B</bold> Heatmap of differentially expressed genes across five transcriptional subtypes of tumor cells. <bold>C</bold> t-SNE plots of tumor cell regions showing subclusters, inferred CNV scores, and deconvolved cell types. <bold>D</bold> Heatmap of differentially expressed genes across three transcriptional subtypes of non-tumor cells. <bold>E</bold> t-SNE plots of non-tumor cell regions displaying subclusters, CNV scores, and cell-type annotations. <bold>F</bold> Spatial maps showing the distribution of neoplastic cells, fibroblasts, endothelial cells, T/NK cells, B cells, myeloid cells, and mast cells in the BRCA2 spatial transcriptomics sample. <bold>G</bold> Heatmap depicting differences in cell-type composition across low-, intermediate-, and high-grade tumors in spatial transcriptomic data.</p></caption><graphic id="d33e431" position="float" orientation="portrait" xlink:href="41746_2025_1967_Fig3_HTML.jpg"/></fig></p></sec><sec id="Sec6"><title>Tumor epithelial subpopulations exhibit transcriptional and developmental heterogeneity</title><p id="Par10">Focusing on neoplastic epithelial cells, we identified seven transcriptionally distinct tumor subpopulations (Fig. <xref rid="Fig4" ref-type="fig">4A</xref>). SCGB2A2+ cells were preferentially enriched in low- and intermediate-grade tumors, but depleted in high-grade samples. These cells expressed SCGB2A2, PIP, TFF1, and AGR2, indicating luminal and secretory differentiation (Fig. <xref rid="Fig4" ref-type="fig">4B</xref>). Functional enrichment revealed distinct pathway associations (Fig. <xref rid="Fig4" ref-type="fig">4C</xref>). Pseudotime analysis suggested SCGB2A2+ cells occupy early differentiation states (Fig. <xref rid="Fig4" ref-type="fig">4D&#8211;G</xref>), with gene dynamics along the trajectory further supporting this (Fig. <xref rid="Fig4" ref-type="fig">4E, H</xref>).<fig id="Fig4" position="float" orientation="portrait"><label>Fig. 4</label><caption><title>Intratumoral epithelial cells exhibit transcriptional heterogeneity and dynamic developmental states.</title><p><bold>A</bold> UMAP plot showing seven transcriptionally distinct subclusters of neoplastic epithelial cells. <bold>B</bold> Heatmap displaying marker gene expression across the seven tumor epithelial subpopulations. <bold>C</bold> Bubble plot showing Gene Ontology Biological Process (GOBP) enrichment analysis of differentially expressed genes among tumor subclusters. <bold>D</bold> Ridge plot showing pseudotime distribution of epithelial tumor cells, indicating dynamic transcriptional transitions. <bold>E</bold> Heatmap of gene expression dynamics along the pseudotime trajectory. <bold>F</bold> Pseudotime trajectory graph revealing bifurcating lineage paths among tumor epithelial cells. <bold>G</bold> Bar plot showing the proportion of each epithelial subpopulation across five inferred pseudotime states. <bold>H</bold> Scatter plots of selected genes (MITF, KIT, VIM, CCL2, C1R, STAT3) showing expression trends along pseudotime.</p></caption><graphic id="d33e484" position="float" orientation="portrait" xlink:href="41746_2025_1967_Fig4_HTML.jpg"/></fig></p></sec><sec id="Sec7"><title>SCGB2A2+ neoplastic cells display distinct lipid metabolism and spatial localization</title><p id="Par11">SCGB2A2+ tumor cells were enriched in low-grade tumors (Fig. <xref rid="Fig5" ref-type="fig">5A</xref>). Differential expression and MSigDB-based scoring revealed heightened lipid metabolic activity in these cells (Fig. <xref rid="Fig5" ref-type="fig">5B, C</xref>). Spatial expression of HOXB2 and fatty acid metabolism signatures confirmed localized enrichment (Fig. <xref rid="Fig5" ref-type="fig">5D, E</xref>), suggesting a unique metabolic phenotype associated with early-stage BRCA.<fig id="Fig5" position="float" orientation="portrait"><label>Fig. 5</label><caption><title>SCGB2A2&#8314; neoplastic cells exhibit distinct lipid metabolic signatures and spatial localization.</title><p><bold>A</bold> Bar plot showing enrichment of SCGB2A2&#8314; tumor cells across different tumor grades. <bold>B</bold> Heatmap of differentially expressed genes between SCGB2A2&#8314; and non-SCGB2A2&#8314; NEO cells. <bold>C</bold> Heatmap showing lipid metabolism-related pathway signature scores comparing SCGB2A2&#8314; and non-SCGB2A2&#8314; NEO cells. <bold>D</bold> Spatial maps of three spatial transcriptomics samples displaying expression of HOXB2 and fatty acid metabolism signature scores. <bold>E</bold> Violin plots showing the distribution of ABNORMAL_CIRCULATING_FATTY_ACID_CONCENTRATION and FATTY_ACID_BETA_OXIDATION pathway scores across four BRCA spatial transcriptomics samples (BRCA_1142243F, BRCA_CID4290, BRCA_CID4465, and BRCA0).</p></caption><graphic id="d33e520" position="float" orientation="portrait" xlink:href="41746_2025_1967_Fig5_HTML.jpg"/></fig></p></sec><sec id="Sec8"><title>T and B lymphocyte subsets define immune landscape and relate to tumor grade and prognosis</title><p id="Par12">Clustering of T and B lymphocytes identified 19 immune subpopulations (Fig. <xref rid="Fig6" ref-type="fig">6A, B</xref>). Low-grade tumors exhibited enrichment of CPB1&#8201;+&#8201;CD4&#8201;+&#8201;T cells (Fig. <xref rid="Fig6" ref-type="fig">6C</xref>). Differential expression and functional analysis revealed heterogeneity in cytokine signaling and cytotoxicity (Fig. <xref rid="Fig6" ref-type="fig">6D&#8211;G</xref>). Notably, C2 (GNLY&#8201;+&#8201;NKT) and C5 (IL7R&#8201;+&#8201;CD8&#8201;+&#8201;) cells displayed opposing functional signatures and were associated with differential cytotoxic and exhaustion scores (Fig. <xref rid="Fig6" ref-type="fig">6H</xref>). Lower C5 infiltration correlated with worse prognosis in TCGA-BRCA (Fig. <xref rid="Fig6" ref-type="fig">6I</xref>).<fig id="Fig6" position="float" orientation="portrait"><label>Fig. 6</label><caption><title>T and B lymphocyte heterogeneity defines immune landscape and correlates with tumor grade and prognosis.</title><p><bold>A</bold> UMAP plot showing 19 transcriptionally distinct T and B lymphocyte clusters. <bold>B</bold> Feature plots of representative marker genes used for lymphocyte subcluster annotation. <bold>C</bold> Bar plot showing the relative abundance of the 19 lymphocyte clusters across low-, intermediate-, and high-grade BRCA tumors. <bold>D</bold> Heatmap of immune-related gene expression across the 19 lymphocyte clusters, highlighting functional diversity. <bold>E</bold> Bar plot showing the grade-specific abundance of cluster C5 (IL7R&#8314; CD8&#8314; T cells). <bold>F</bold> Ridge plots displaying the expression of cytotoxic effector genes (GZMB, GZMH, PRF1, GNLY) in CD8&#8314; T cell subsets. <bold>G</bold> Volcano plots of differentially expressed genes across selected lymphocyte subpopulations. <bold>H</bold> Violin plots comparing cytotoxicity and exhaustion scores among CD8&#8314; T cell subtypes. <bold>I</bold> Kaplan&#8211;Meier survival analysis showing prognosis stratification based on C5 (IL7R&#8314; CD8&#8314;) T cell abundance (high vs. low) using TCGA-BRCA data.</p></caption><graphic id="d33e576" position="float" orientation="portrait" xlink:href="41746_2025_1967_Fig6_HTML.jpg"/></fig></p></sec><sec id="Sec9"><title>Myeloid subtypes exhibit divergent immunoregulatory programs and polarization states</title><p id="Par13">Reclustering of myeloid cells yielded 12 subpopulations with distinct transcriptional and functional profiles (Fig. <xref rid="Fig7" ref-type="fig">7A&#8211;D</xref>). Pathway enrichment revealed diversity in immune modulation and inflammation (Fig. <xref rid="Fig7" ref-type="fig">7C</xref>). Low-grade tumors harbored a higher proportion of C1 cells (Fig. <xref rid="Fig7" ref-type="fig">7E</xref>). Pseudotime and polarization analyses showed bifurcated differentiation paths, with C3 enriched for M1 and C5 for M2 polarization (Fig. <xref rid="Fig7" ref-type="fig">7F&#8211;H</xref>).<fig id="Fig7" position="float" orientation="portrait"><label>Fig. 7</label><caption><title>Myeloid subtypes display diverse immunoregulatory programs and polarization states in BRCA.</title><p><bold>A</bold> UMAP plot showing 12 transcriptionally defined myeloid cell subpopulations, including monocytes, macrophages, and dendritic cells. <bold>B</bold> Feature plots displaying the expression of representative marker genes across myeloid subclusters. <bold>C</bold> Heatmap of hallmark gene set enrichment scores across the 12 myeloid subtypes, illustrating functional heterogeneity. <bold>D</bold> Volcano plots of differentially expressed genes among selected myeloid subtypes. <bold>E</bold> Pie charts showing the distribution of each myeloid subtype across low-, intermediate-, and high-grade tumors. <bold>F</bold> Pseudotime trajectory analysis of macrophage differentiation states, suggesting bifurcating lineage paths. <bold>G</bold> UMAP plots showing the distribution of M1 and M2 macrophage signature scores across myeloid subclusters. <bold>H</bold> Violin plots comparing M1 and M2 polarization scores among the identified macrophage subpopulations.</p></caption><graphic id="d33e625" position="float" orientation="portrait" xlink:href="41746_2025_1967_Fig7_HTML.jpg"/></fig></p></sec><sec id="Sec10"><title>Stromal subtypes demonstrate histology-dependent distributions and spatial localization</title><p id="Par14">Reclustering stromal cells identified 14 subtypes (Fig. <xref rid="Fig8" ref-type="fig">8A</xref>), including CAFs, iCAFs, myoCAFs, and multiple endothelial lineages (Fig. <xref rid="Fig8" ref-type="fig">8D</xref>). Subtypes showed grade-specific distributions (Fig. <xref rid="Fig8" ref-type="fig">8B, C</xref>) and distinct gene signatures (Fig. <xref rid="Fig8" ref-type="fig">8E</xref>). Integration with spatial data demonstrated spatially compartmentalized stromal populations across histological subtypes (Fig. <xref rid="Fig8" ref-type="fig">8F</xref>).<fig id="Fig8" position="float" orientation="portrait"><label>Fig. 8</label><caption><title>Stromal subtypes demonstrate histology-dependent distributions and spatial compartmentalization.</title><p><bold>A</bold> UMAP plot showing reclustering of stromal cells into 14 transcriptionally distinct subtypes. <bold>B</bold> UMAP plots of the 14 stromal subtypes stratified by tumor grade (low, intermediate, high). <bold>C</bold> Bar plot showing the proportional abundance of each stromal subtype across tumor grades. <bold>D</bold> Feature plots displaying expression of representative marker genes. <bold>E</bold> Heatmap of differentially expressed genes among the 14 stromal subtypes. <bold>F</bold> Spatial maps from spatial transcriptomics samples showing the localized distribution of fibroblasts and endothelial cells within tumor tissues.</p></caption><graphic id="d33e671" position="float" orientation="portrait" xlink:href="41746_2025_1967_Fig8_HTML.jpg"/></fig></p></sec><sec id="Sec11"><title>Fibroblast subtype F3 associates with low-grade tumors and favors prognosis</title><p id="Par15">Focused reclustering of fibroblasts identified subtype F3 as enriched in low-grade tumors (Supplementary Fig. <xref rid="MOESM1" ref-type="media">1A, B</xref>). EEF1A1 was overexpressed in high-grade fibroblasts and associated with better survival in TCGA-BRCA (Supplementary Fig. <xref rid="MOESM1" ref-type="media">1C, D</xref>). ssGSEA scoring and survival analysis revealed favorable prognosis in patients with low-grade-associated fibroblast gene expression (Supplementary Fig. <xref rid="MOESM1" ref-type="media">1E, F</xref>).</p></sec><sec id="Sec12"><title>Low-grade-enriched stromal and immune subtypes engage in conserved ligand-receptor signaling</title><p id="Par16">We identified F3_CXCR4 (fibroblast), M1_IGKC (myeloid), and E4_CLU (endothelial) as low-grade-enriched subtypes. NicheNet analysis predicted ligand-receptor signaling from these cells to the broader TME (Supplementary Fig. <xref rid="MOESM1" ref-type="media">2A&#8211;C</xref>), and shared ligands were identified (Supplementary Fig. <xref rid="MOESM1" ref-type="media">2D</xref>). CellChat analysis quantified signaling flux and directionality (Supplementary Fig. <xref rid="MOESM1" ref-type="media">2E&#8211;G</xref>), highlighting conserved ligand-receptor interactions among these subtypes (Supplementary Fig. <xref rid="MOESM1" ref-type="media">2F&#8211;H</xref>).</p></sec><sec id="Sec13"><title>Spatial mapping validates localization of low-grade-enriched functional subtypes</title><p id="Par17">Using spatial transcriptomic data, we validated the distribution of CLU, CXCR4, and IGKC as markers of E4_CLU, F3_CXCR4, and M1_IGKC, respectively (Supplementary Fig. <xref rid="MOESM1" ref-type="media">3A&#8211;C</xref>). CellTrek mapping confirmed spatial compartmentalization of these subtypes within tumor tissues (Supplementary Fig. <xref rid="MOESM1" ref-type="media">3D</xref>), supporting their biological relevance in early-stage BRCA.</p></sec><sec id="Sec14"><title>Bulk RNA-Seq analysis confirms clinical relevance of low-grade-enriched subtypes</title><p id="Par18">To validate the presence and clinical relevance of low-grade-enriched stromal-immune populations, we performed bulk RNA-seq deconvolution on TCGA-BRCA using BisqueRNA with our single-cell dataset as reference. This revealed the proportional abundance of major cell types&#8212;including five endothelial, seven fibroblast, and nine myeloid subtypes&#8212;alongside neoplastic, mast, and T/NK cells (Supplementary Fig. <xref rid="MOESM1" ref-type="media">4A</xref>). Focusing on three low-grade-enriched populations&#8212;F3_CXCR4 fibroblasts, M1_IGKC myeloid cells, and E4_CLU endothelial cells&#8212;we calculated a composite Score representing their summed abundance. This Score stratified tumors along clinical staging dimensions. Notably, patients with M0 status predominantly exhibited high Scores, while M1 patients (indicating metastasis) showed mostly low Scores, suggesting these cell types are depleted in metastatic disease (Supplementary Fig. <xref rid="MOESM1" ref-type="media">4B</xref>, left). Similarly, T1-stage patients (early primary tumors) were mainly enriched for high Scores, whereas T2&#8211;T4 stages were associated with low Scores, indicating reduced abundance of these stromal-immune populations in more advanced tumors (Supplementary Fig. <xref rid="MOESM1" ref-type="media">5B</xref>, right). Boxplot comparisons confirmed a significant inverse association between Score (and individual subtype abundance) and both pT and pM stages (Supplementary Fig. <xref rid="MOESM1" ref-type="media">4C</xref>). Further analyses revealed functional and molecular implications of this stratification: gene ontology analysis of tumors with high vs. low Scores showed enrichment for immune signaling and stromal remodeling pathways in high-Score samples (Supplementary Fig. <xref rid="MOESM1" ref-type="media">4D</xref>). Unsupervised clustering (k&#8201;=&#8201;5) of TCGA-BRCA samples based on deconvolved subtype signatures revealed five molecular subgroups with distinct expression profiles (Supplementary Fig. <xref rid="MOESM1" ref-type="media">4E</xref>). Spatial transcriptomics via CARD further validated the localization of these cell types in tumor sections (Supplementary Fig. <xref rid="MOESM1" ref-type="media">4F</xref>), supporting their biological relevance in shaping the low-grade tumor microenvironment.</p></sec><sec id="Sec15"><title>Enhanced CCL5 signaling and abundance of low-grade subtypes define low-grade tumor ecosystem</title><p id="Par19">We observed greater T/NK cell abundance in low-grade tumors (Supplementary Fig. <xref rid="MOESM1" ref-type="media">5A</xref>). CellChat analysis revealed enhanced communication&#8212;particularly CCL5 signaling&#8212;between immune cells and low-grade-enriched subtypes in low-grade tumors (Supplementary Fig. <xref rid="MOESM1" ref-type="media">5B, C</xref>). Quantification confirmed enrichment of F3_CXCR4, M1_IGKC, and E4_CLU in low-grade tumors (Supplementary Fig. <xref rid="MOESM1" ref-type="media">5D&#8211;G</xref>).</p></sec><sec id="Sec16"><title>Low-grade-enriched subtypes correlate with immunotherapy</title><p id="Par20">Despite being enriched in low-grade tumors, the identified subtypes appeared paradoxically linked to immunotherapy non-responsiveness. Using the TIDE algorithm, we found that higher expression of CLU (E4_CLU marker) and CXCR4 (F3_CXCR4 marker) was significantly associated with predicted non-responder status (Supplementary Fig. <xref rid="MOESM1" ref-type="media">6A, B</xref>). Moreover, tumors with higher composite Scores&#8212;enriched in these low-grade-associated subtypes&#8212;also showed reduced predicted response to immune checkpoint blockade (Supplementary Fig. <xref rid="MOESM1" ref-type="media">6C</xref>). Further comparison between predicted responders and non-responders revealed significantly greater abundance of F3_CXCR4 fibroblasts, M1_IGKC myeloid cells, and E4_CLU endothelial cells in the non-responder group (Supplementary Fig. <xref rid="MOESM1" ref-type="media">6D&#8211;F</xref>).</p></sec><sec id="Sec17"><title>Cell&#8211;cell communication networks reveal grade-specific signaling pathways in BRCA</title><p id="Par21">To further dissect how intercellular signaling evolves with tumor progression, we mapped global ligand&#8211;receptor networks across tumor grades. High-grade tumors exhibited broader and more complex signaling connectivity compared to low-grade ones (Supplementary Fig. <xref rid="MOESM1" ref-type="media">7A, B</xref>). We identified MDK signaling as a major pathway upregulated in high-grade tumors, primarily secreted by fibroblasts and tumor epithelial cells (Supplementary Fig. <xref rid="MOESM1" ref-type="media">7C</xref>), potentially promoting proliferation and angiogenesis. Similarly, Galectin signaling&#8212;predominantly produced by myeloid and mast cells&#8212;was also enhanced in high-grade tumors (Supplementary Fig. <xref rid="MOESM1" ref-type="media">7D</xref>). Spatial transcriptomic analysis revealed differential expression of LGALS9-CD44 and LGALS9-HAVCR2 ligand&#8211;receptor pairs across tumor sections (Supplementary Fig. <xref rid="MOESM1" ref-type="media">7E</xref>), suggesting that Galectin-9&#8211;mediated signaling may facilitate immune suppression in advanced BRCA.</p></sec></sec><sec id="Sec18" sec-type="discussion"><title>Discussion</title><p id="Par22">In this study, we constructed a comprehensive multi-omic atlas delineating the cellular heterogeneity and spatial architecture of the breast cancer TME across tumor grades. Our integrative analysis combining single-cell RNA sequencing, spatial transcriptomics, and bulk RNA-seq deconvolution revealed distinct stromal and immune subpopulations preferentially enriched in low-grade tumors, including F3_CXCR4 fibroblasts, M1_IGKC myeloid cells, and E4_CLU endothelial cells. These subtypes exhibited unique functional programs and spatial compartmentalization, implicating their critical roles in shaping early tumor ecosystems. Interestingly, despite their association with favorable prognosis and low-grade status, these cell populations correlated with reduced predicted responsiveness to immune checkpoint blockade, suggesting a complex interplay between the TME composition and immunotherapy efficacy.</p><p id="Par23">The TIME plays a pivotal role in shaping disease progression and clinical outcomes in BRCA<sup><xref ref-type="bibr" rid="CR19">19</xref>,<xref ref-type="bibr" rid="CR20">20</xref></sup>. Modulating the immunosuppressive aspects of the TIME to boost anti-cancer immune responses represents a key objective of contemporary cancer immunotherapy. Strategies targeting different components of the TIME, such as immune checkpoint molecules and regulatory immune cells, have been designed to augment the immune system&#8217;s capacity to detect and destroy cancer cells. These approaches have shown substantial efficacy across various cancer types, leading to the development of promising treatments like immune checkpoint inhibitors (ICIs) and adoptive cell therapies. The role of epigenetics in regulating immune responses, including immune cell differentiation, activation, and infiltration into tumors, has been particularly noted, suggesting that epigenetic reprogramming of the TIME could be a viable therapeutic approach<sup><xref ref-type="bibr" rid="CR21">21</xref></sup>. Ongoing research and clinical trials are exploring this potential, aiming to harness these mechanisms for more effective cancer treatments<sup><xref ref-type="bibr" rid="CR22">22</xref></sup>. Our study reveals distinct cellular behaviors in tumor cell subtypes and immune cells, specifically highlighting differences in gene expression and cellular functions that influence lipid metabolism and tumor dynamics. Separate analyses of myeloid and stromal cells provide insights into their unique identities and functional states, while the exploration of cell communication patterns offers a deeper understanding of the interactions within the tumor microenvironment.</p><p id="Par24">HOX genes, including HOXB2, are crucial regulatory genes conserved across species, playing significant roles in embryonic development and cellular processes<sup><xref ref-type="bibr" rid="CR23">23</xref></sup>. HOXB2 has been identified as a gene that functions variably as an oncogene or a tumor suppressor in various cancers, affecting tumor growth, progression, and metastasis<sup><xref ref-type="bibr" rid="CR24">24</xref>,<xref ref-type="bibr" rid="CR25">25</xref></sup>. It has been implicated in the tumorigenesis of multiple cancer types such as breast, lung, cervical, esophageal, glioblastoma, ovarian, and colorectal cancers<sup><xref ref-type="bibr" rid="CR26">26</xref>&#8211;<xref ref-type="bibr" rid="CR29">29</xref></sup>. In specific cancer contexts, such as triple-negative breast cancer (TNBC), HOXB2 levels are notably decreased, affecting cancer progression and prognosis negatively. A study identified the antisense RNA HOXB-AS1 as a guide molecule that facilitates the addition of the H3K4me3 mark by SMYD3 to the HOXB2 promoter region in non-TNBC, promoting HOXB2 expression. However, the low expression of HOXB-AS1 in TNBC leads to reduced HOXB2 levels, subsequently downregulating the ECM2 transcriptional network and MATN3, which are linked to more aggressive cancer progression, EMT-like characteristics, and poor prognosis<sup><xref ref-type="bibr" rid="CR30">30</xref></sup>. In contrast, forced expression of HOXB2 in TNBC models suppresses invasive and migratory behaviors and inhibits tumor growth and metastasis in vivo<sup><xref ref-type="bibr" rid="CR31">31</xref>,<xref ref-type="bibr" rid="CR32">32</xref></sup>. Furthermore, HOXB2 downregulation correlates with poorer overall survival (OS) not only in breast cancer patients but also in those with other solid tumors. Notably, overexpression of HOXB2 has been associated with better prognostic outcomes. In breast cancer, specifically, lower HOXB2 expression levels have been significantly associated with higher grade tumors, suggesting its protective role against tumor aggressiveness<sup><xref ref-type="bibr" rid="CR32">32</xref></sup>. Collectively, these findings underscore HOXB2 complex role in cancer biology, acting both as an oncogene and a tumor suppressor depending on the cancer type and cellular context, with a profound impact on cancer dynamics and therapeutic outcomes. In our study, among the seven subtypes of tumor cells, SCGB2A2&#8201;+&#8201;NEO was found to be more abundant in medium-high-grade breast cancer than in low-grade breast cancer. Within this SCGB2A2&#8314; subtype, cells with high HOXB2 expression exhibited significantly higher ABNORMAL_CIRCULATING_FATTY_ACID_CONCENTRATION scores than HOXB2-low malignant cells, suggesting a potential regulatory role of HOXB2 in fatty acid metabolism. Previous studies have indicated that the expression of HOX genes is associated with lipid accumulation during adipocyte differentiation. More specifically, HOXA5 has been shown to promote adipogenesis by increasing DNA methylation and inhibiting the PKA/HSL signaling pathway in mouse models. These findings collectively imply a potential mechanistic involvement of HOXB2 in regulating lipid metabolism. In addition, a large number of literatures have pointed out that abnormal fatty acid metabolism promotes the occurrence and development of tumors, and has become an important therapeutic target<sup><xref ref-type="bibr" rid="CR33">33</xref>&#8211;<xref ref-type="bibr" rid="CR35">35</xref></sup>. For instance, tumor-derived arachidonic acid has been shown to reprogram neutrophils toward an immunosuppressive phenotype and promote therapy resistance in TNBC.</p><p id="Par25">We also explored the prognostic implications of immune subpopulations. IL7R&#8314; CD8&#8314; T cells, identified from single-cell data, were associated with a favorable prognosis in TCGA BRCA patients. IL7R is known to regulate T cell development, survival, and homeostasis through both membrane-bound and soluble isoforms<sup><xref ref-type="bibr" rid="CR36">36</xref>&#8211;<xref ref-type="bibr" rid="CR42">42</xref></sup>. Although IL7 signaling promotes proliferation in certain hematologic malignancies, it also plays vital roles in anti-tumor immunity<sup><xref ref-type="bibr" rid="CR43">43</xref>&#8211;<xref ref-type="bibr" rid="CR51">51</xref></sup>. As a result, IL7R-targeted therapies, including CAR-T cells and JAK/STAT inhibitors, have emerged as promising avenues in both autoimmune diseases and cancer immunotherapy<sup><xref ref-type="bibr" rid="CR52">52</xref>&#8211;<xref ref-type="bibr" rid="CR62">62</xref></sup>.</p><p id="Par26">Furthermore, our spatial transcriptomic analysis identified the LGALS9&#8211;CD44 ligand&#8211;receptor pair as a key mediator in the GALECTIN signaling network, with broad expression across immune and tumor compartments. Galectin-9 (Gal-9), encoded by LGALS9, is a tandem-repeat-type galectin with immunomodulatory properties, particularly through binding to CD44 on regulatory T cells to enhance their stability and suppressive function<sup><xref ref-type="bibr" rid="CR63">63</xref>&#8211;<xref ref-type="bibr" rid="CR71">71</xref></sup>. Interestingly, recent studies have suggested that Gal-9 also possesses anti-metastatic properties in breast cancer by promoting tumor cell aggregation and reducing extracellular matrix adhesion, thereby inhibiting dissemination<sup><xref ref-type="bibr" rid="CR72">72</xref>,<xref ref-type="bibr" rid="CR73">73</xref></sup>. Our findings reinforce the emerging role of LGALS9&#8211;CD44 interactions in immune regulation and tumor suppression, and position them as potential therapeutic targets.</p><p id="Par27">In summary, our study provides a comprehensive characterization of the BRCA tumor ecosystem across multiple cellular dimensions. By integrating single-cell and spatial transcriptomics, we uncovered critical regulators such as HOXB2, IL7R, and LGALS9, offering novel insights into tumor&#8211;immune&#8211;stromal interactions and potential avenues for targeted therapy.</p><p id="Par28">This study is limited by its reliance on publicly available datasets and computational predictions without direct experimental validation. Key findings, including the functional roles of HOXB2 and LGALS9&#8211;CD44 signaling, require further confirmation through in vitro and in vivo experiments. Additionally, the modest spatial transcriptomics sample size and heterogeneity among datasets constrain the generalizability of our conclusions. Future work will focus on integrating additional multi-omics data and validating candidate targets in independent patient cohorts to strengthen clinical applicability and guide therapeutic development.</p><p id="Par29">In summary, our integrative multi-omic analysis elucidates the complex cellular composition, functional states, and spatial organization of the BRCA tumor microenvironment. The identification of low-grade-enriched stromal and immune subtypes with distinct signaling profiles enhances our understanding of tumor progression and immune modulation. These findings provide a valuable framework for the development of tailored therapeutic strategies targeting the TME to improve clinical outcomes in breast cancer.</p></sec><sec id="Sec19"><title>Methods</title><sec id="Sec20"><title>Data acquisition and preprocessing</title><p id="Par30">Bulk RNA-sequencing data and matched clinical information for BRCA were obtained from TCGA via the UCSC Xena browser (<ext-link ext-link-type="uri" xlink:href="https://xenabrowser.net">https://xenabrowser.net</ext-link>). Samples lacking survival data were excluded, resulting in 1082 cases for downstream survival analyses. Raw counts were normalized to transcripts per million (TPM) and log2-transformed prior to analysis.</p><p id="Par31">scRNA-seq datasets of BRCA primary tumors were retrieved from the Gene Expression Omnibus (GEO) database (<ext-link ext-link-type="pmc:entrez-geo" xlink:href="GSE203612">GSE203612</ext-link>, <ext-link ext-link-type="pmc:entrez-geo" xlink:href="GSE114725">GSE114725</ext-link>, <ext-link ext-link-type="pmc:entrez-geo" xlink:href="GSE176078">GSE176078</ext-link>), encompassing 59 samples in total. Spatial transcriptomics data included nine primary tumor samples from GEO (<ext-link ext-link-type="pmc:entrez-geo" xlink:href="GSE203612">GSE203612</ext-link>) and Zenodo (zenodo.4739739). All analyses were performed using R software (version 4.1.3) and relevant packages.</p></sec><sec id="Sec21"><title>Single-cell RNA-seq data processing and quality control</title><p id="Par32">Raw scRNA-seq data were processed with the Seurat package. Quality control criteria filtered cells with mitochondrial gene content exceeding 20%, unique molecular identifier (UMI) counts between 200 and 20,000, and detected gene numbers ranging from 200 to 6000. Data normalization was employed using Seurat&#8217;s NormalizeData function. The top 2000 highly variable genes were identified using FindVariableFeatures. To mitigate cell cycle effects, cell cycle scores (S.Score and G2M.Score) were regressed out during data scaling (ScaleData). Batch effects across datasets were corrected with Harmony integration. Dimensionality reduction was performed using UMAP and t-SNE, and clustering utilized the Louvain algorithm implemented in Seurat.</p></sec><sec id="Sec22"><title>Cell type annotation and subclustering</title><p id="Par33">Major cell populations were annotated based on canonical marker genes: epithelial cells (EPCAM, KRT18, KRT19, CDH1), fibroblasts (DCN, THY1, COL1A1, COL1A2), endothelial cells (PECAM1, CLDN5, FLT1, RAMP2), T cells (CD3D, CD3E, CD3G, TRAC), NK cells (NKG7, GNLY, NCAM1, KLRD1), B cells (CD79A, IGHM, IGHG3, IGHA2), myeloid cells (LYZ, MARCO, CD68, FCGR3A), and mast cells (KIT, MS4A2, GATA2). Separate subclustering of epithelial, stromal, and immune compartments was performed to explore intrapopulation heterogeneity, with marker genes used for refined subtype identification.</p></sec><sec id="Sec23"><title>Copy number variation (CNV) analysis</title><p id="Par34">To distinguish malignant epithelial subpopulations, inferCNV was applied using normal epithelial cells as a reference. CNV profiles were inferred to identify tumor-specific chromosomal alterations.</p></sec><sec id="Sec24"><title>Pseudotime trajectory analysis</title><p id="Par35">Monocle2 was employed for pseudotime ordering of epithelial cell subclusters, using the DDRTree algorithm for dimensionality reduction and default parameters, to infer developmental trajectories and differentiation states.</p></sec><sec id="Sec25"><title>Transcription factor regulatory network analysis</title><p id="Par36">SCENIC analysis was conducted to identify active transcription factor (TF) regulons within cell subpopulations. The workflow utilized RcisTarget and GRNBoost motif databases, with AUCell scoring quantifying regulon activity across cells.</p></sec><sec id="Sec26"><title>Spatial transcriptomics processing and deconvolution</title><p id="Par37">Spatial transcriptomic datasets were quality-controlled and normalized using the SCT transform method. An average of ~2466 spots per sample was analyzed, with mean UMI counts ~9594 and mitochondrial content ~4.3%. Cell-type deconvolution for each spot was performed using the conditional autoregression-based deconvolution (CARD) algorithm, leveraging single-cell-derived cell-type annotations to predict spot-level cellular compositions.</p></sec><sec id="Sec27"><title>Cell&#8211;cell communication analysis</title><p id="Par38">Intercellular communication networks were inferred using the CellChat package. Normalized expression matrices were input to construct CellChat objects, followed by the identification of expressed ligand-receptor pairs and signaling pathways with default parameters. Communication probabilities and pathway-specific interactions were computed, and aggregated networks were visualized to reveal grade-dependent signaling alterations.</p></sec><sec id="Sec28"><title>Statistical analysis</title><p id="Par39">Statistical analyses and visualizations were conducted in R (v4.1.3). Pearson correlation assessed relationships between continuous variables. Categorical comparisons employed chi-square tests, while Wilcoxon rank-sum or Student&#8217;s <italic toggle="yes">t</italic> tests were used for continuous data, depending on normality. Optimal cutoff points for survival analysis were determined using the survminer package. Kaplan&#8211;Meier survival curves and Cox proportional hazards regression models were generated with the survival package, with two-sided <italic toggle="yes">p</italic> values&#8201;&lt;&#8201;0.05 considered statistically significant.</p></sec></sec><sec id="Sec29" sec-type="supplementary-material"><title>Supplementary information</title><p>
<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xlink:href="41746_2025_1967_MOESM1_ESM.pdf" position="float" orientation="portrait"><caption><p>Supplementary Figure</p></caption></media></supplementary-material>
</p></sec></body><back><fn-group><fn><p><bold>Publisher&#8217;s note</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>These authors contributed equally: Junjie Kuang, Guofang Zhong, Linfeng Zhao.</p></fn></fn-group><sec><title>Supplementary information</title><p>The online version contains supplementary material available at 10.1038/s41746-025-01967-7.</p></sec><ack><title>Acknowledgements</title><p>This work was supported by the Guangdong Basic and Applied Basic Research Foundation (Regional Joint Fund - Regional Cultivation Project, Grant No. 2023A1515140039), the Research Cultivation and Innovation Fund of Huizhou First Hospital (Key Cultivation Project Grant No. 2024ZD002; Youth Cultivation Project Grant Nos. 2024QN001 and 2024QN004), and the Huizhou Science and Technology Research and Development Program (Grant No. 2024CZ010001).</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>J.K. and X.Y. performed data analysis and interpretation. G.Z. and L.Z. contributed to data acquisition and figure preparation. Y.Z. and J.L. conceptualized the study, supervised the project, and revised the manuscript. All authors read and approved the final manuscript.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The datasets used in this study are publicly available. Bulk RNA-sequencing data for BRCA were obtained from TCGA via UCSC Xena (<ext-link ext-link-type="uri" xlink:href="https://xenabrowser.net">https://xenabrowser.net</ext-link>). scRNA-seq data were retrieved from GEO (accession numbers: <ext-link ext-link-type="pmc:entrez-geo" xlink:href="GSE203612">GSE203612</ext-link>, <ext-link ext-link-type="pmc:entrez-geo" xlink:href="GSE114725">GSE114725</ext-link>, <ext-link ext-link-type="pmc:entrez-geo" xlink:href="GSE176078">GSE176078</ext-link>). Spatial transcriptomics data are available from GEO (<ext-link ext-link-type="pmc:entrez-geo" xlink:href="GSE203612">GSE203612</ext-link>) and Zenodo (zenodo.4739739). All data used in the study are fully accessible within this article.</p></notes><notes notes-type="data-availability"><title>Code availability</title><p>The code used for the analysis in this study is available upon reasonable request.</p></notes><notes id="FPar1" notes-type="COI-statement"><title>Competing interests</title><p id="Par40">The authors declare no competing interests.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sung</surname><given-names>H</given-names></name><etal/></person-group><article-title>Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title><source>CA Cancer J. Clin.</source><year>2021</year><volume>71</volume><fpage>209</fpage><lpage>249</lpage><pub-id pub-id-type="pmid">33538338</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3322/caac.21660</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Sung, H. et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. <italic toggle="yes">CA Cancer J. Clin.</italic><bold>71</bold>, 209&#8211;249 (2021).<pub-id pub-id-type="pmid">33538338</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3322/caac.21660</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Siegel</surname><given-names>RL</given-names></name><name name-style="western"><surname>Giaquinto</surname><given-names>AN</given-names></name><name name-style="western"><surname>Jemal</surname><given-names>A</given-names></name></person-group><article-title>Cancer Statist.</article-title><source>CA Cancer J. Clin.</source><year>2024</year><volume>74</volume><fpage>12</fpage><lpage>49</lpage><pub-id pub-id-type="pmid">38230766</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3322/caac.21820</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Siegel, R. L., Giaquinto, A. N. &amp; Jemal, A. Cancer Statist. <italic toggle="yes">CA Cancer J. Clin.</italic><bold>74</bold>, 12&#8211;49 (2024).<pub-id pub-id-type="pmid">38230766</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3322/caac.21820</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>CJ</given-names></name><etal/></person-group><article-title>The molecular mechanism of epithelial-mesenc hymal transition for breast carcinogenesis</article-title><source>Biomolecules</source><year>2019</year><volume>9</volume><fpage>476</fpage><pub-id pub-id-type="pmid">31514467</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/biom9090476</pub-id><pub-id pub-id-type="pmcid">PMC6770718</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Li, C. J. et al. The molecular mechanism of epithelial-mesenc hymal transition for breast carcinogenesis. <italic toggle="yes">Biomolecules</italic><bold>9</bold>, 476 (2019).<pub-id pub-id-type="pmid">31514467</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/biom9090476</pub-id><pub-id pub-id-type="pmcid">PMC6770718</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tzeng</surname><given-names>YT</given-names></name><etal/></person-group><article-title>Integrated analysis of pivotal biomarker of LSM1, immune cell infiltration and therapeutic drugs in breast cancer</article-title><source>J. Cell Mol. Med.</source><year>2022</year><volume>26</volume><fpage>4007</fpage><lpage>4020</lpage><pub-id pub-id-type="pmid">35692083</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jcmm.17436</pub-id><pub-id pub-id-type="pmcid">PMC9279588</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Tzeng, Y. T., et al. Integrated analysis of pivotal biomarker of LSM1, immune cell infiltration and therapeutic drugs in breast cancer. <italic toggle="yes">J. Cell Mol. Med.</italic><bold>26</bold>, 4007&#8211;4020 (2022).<pub-id pub-id-type="pmid">35692083</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jcmm.17436</pub-id><pub-id pub-id-type="pmcid">PMC9279588</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>M&#252;ller</surname><given-names>V</given-names></name><etal/></person-group><article-title>Epidemiology, clinical outcomes, and unmet needs of patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases: a systematic literature review</article-title><source>Cancer Treat. Rev.</source><year>2023</year><volume>115</volume><fpage>102527</fpage><pub-id pub-id-type="pmid">36893691</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ctrv.2023.102527</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">M&#252;ller, V. et al. Epidemiology, clinical outcomes, and unmet needs of patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases: a systematic literature review. <italic toggle="yes">Cancer Treat. Rev.</italic><bold>115</bold>, 102527 (2023).<pub-id pub-id-type="pmid">36893691</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ctrv.2023.102527</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gluz</surname><given-names>O</given-names></name><name name-style="western"><surname>Graeser</surname><given-names>M</given-names></name></person-group><article-title>Molecular profiling in Early ER&#8201;+&#8201;breast cancer to aid systemic therapy decisions</article-title><source>Curr. Oncol. Rep.</source><year>2023</year><volume>25</volume><fpage>491</fpage><lpage>500</lpage><pub-id pub-id-type="pmid">36862337</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11912-023-01377-6</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Gluz, O. &amp; Graeser, M. Molecular profiling in Early ER&#8201;+&#8201;breast cancer to aid systemic therapy decisions. <italic toggle="yes">Curr. Oncol. Rep.</italic><bold>25</bold>, 491&#8211;500 (2023).<pub-id pub-id-type="pmid">36862337</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11912-023-01377-6</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tzeng</surname><given-names>YT</given-names></name><etal/></person-group><article-title>Breast cancer organoids derived from patients: a platform for tailored drug screening</article-title><source>Biochem Pharm.</source><year>2023</year><volume>217</volume><fpage>115803</fpage><pub-id pub-id-type="pmid">37709150</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bcp.2023.115803</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Tzeng, Y. T. et al. Breast cancer organoids derived from patients: a platform for tailored drug screening. <italic toggle="yes">Biochem Pharm.</italic><bold>217</bold>, 115803 (2023).<pub-id pub-id-type="pmid">37709150</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bcp.2023.115803</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hammond</surname><given-names>ME</given-names></name><etal/></person-group><article-title>American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer</article-title><source>J. Clin. Oncol.</source><year>2010</year><volume>28</volume><fpage>2784</fpage><lpage>2795</lpage><pub-id pub-id-type="pmid">20404251</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2009.25.6529</pub-id><pub-id pub-id-type="pmcid">PMC2881855</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Hammond, M. E. et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. <italic toggle="yes">J. Clin. Oncol.</italic><bold>28</bold>, 2784&#8211;2795 (2010).<pub-id pub-id-type="pmid">20404251</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2009.25.6529</pub-id><pub-id pub-id-type="pmcid">PMC2881855</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nielsen</surname><given-names>TO</given-names></name><etal/></person-group><article-title>Assessment of Ki67 in breast cancer: updated recommendations from the International Ki67 in Breast Cancer Working Group</article-title><source>J. Natl. Cancer Inst.</source><year>2021</year><volume>113</volume><fpage>808</fpage><lpage>819</lpage><pub-id pub-id-type="pmid">33369635</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jnci/djaa201</pub-id><pub-id pub-id-type="pmcid">PMC8487652</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Nielsen, T. O. et al. Assessment of Ki67 in breast cancer: updated recommendations from the International Ki67 in Breast Cancer Working Group. <italic toggle="yes">J. Natl. Cancer Inst.</italic><bold>113</bold>, 808&#8211;819 (2021).<pub-id pub-id-type="pmid">33369635</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jnci/djaa201</pub-id><pub-id pub-id-type="pmcid">PMC8487652</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cardoso</surname><given-names>F</given-names></name><etal/></person-group><article-title>70-gene signature as an aid to treatment decisions in early-stage breast cancer</article-title><source>N. Engl. J. Med.</source><year>2016</year><volume>375</volume><fpage>717</fpage><lpage>729</lpage><pub-id pub-id-type="pmid">27557300</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1602253</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Cardoso, F. et al. 70-gene signature as an aid to treatment decisions in early-stage breast cancer. <italic toggle="yes">N. Engl. J. Med.</italic><bold>375</bold>, 717&#8211;729 (2016).<pub-id pub-id-type="pmid">27557300</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1602253</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qian</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Prognostic cancer gene expression signatures: current status and challenges</article-title><source>Cells</source><year>2021</year><volume>10</volume><fpage>648</fpage><pub-id pub-id-type="pmid">33804045</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cells10030648</pub-id><pub-id pub-id-type="pmcid">PMC8000474</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Qian, Y. et al. Prognostic cancer gene expression signatures: current status and challenges. <italic toggle="yes">Cells</italic><bold>10</bold>, 648 (2021).<pub-id pub-id-type="pmid">33804045</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cells10030648</pub-id><pub-id pub-id-type="pmcid">PMC8000474</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>J&#233;z&#233;quel</surname><given-names>P</given-names></name><etal/></person-group><article-title>Identification of three subtypes of triple-negative breast cancer with potential therapeutic implications</article-title><source>Breast Cancer Res.</source><year>2019</year><volume>21</volume><fpage>65</fpage><pub-id pub-id-type="pmid">31101122</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13058-019-1148-6</pub-id><pub-id pub-id-type="pmcid">PMC6525459</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">J&#233;z&#233;quel, P. et al. Identification of three subtypes of triple-negative breast cancer with potential therapeutic implications. <italic toggle="yes">Breast Cancer Res.</italic><bold>21</bold>, 65 (2019).<pub-id pub-id-type="pmid">31101122</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13058-019-1148-6</pub-id><pub-id pub-id-type="pmcid">PMC6525459</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pollard</surname><given-names>JW</given-names></name></person-group><article-title>Tumour-educated macrophages promote tumour progression and metastasis</article-title><source>Nat. Rev. Cancer</source><year>2004</year><volume>4</volume><fpage>71</fpage><lpage>78</lpage><pub-id pub-id-type="pmid">14708027</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrc1256</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Pollard, J. W. Tumour-educated macrophages promote tumour progression and metastasis. <italic toggle="yes">Nat. Rev. Cancer</italic><bold>4</bold>, 71&#8211;78 (2004).<pub-id pub-id-type="pmid">14708027</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrc1256</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barriga</surname><given-names>V</given-names></name><etal/></person-group><article-title>The complex interaction between the tumor micro-environment and immune checkpoints in breast cancer</article-title><source>Cancers</source><year>2019</year><volume>11</volume><fpage>1205</fpage><pub-id pub-id-type="pmid">31430935</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers11081205</pub-id><pub-id pub-id-type="pmcid">PMC6721629</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Barriga, V. et al. The complex interaction between the tumor micro-environment and immune checkpoints in breast cancer. <italic toggle="yes">Cancers</italic><bold>11</bold>, 1205 (2019).<pub-id pub-id-type="pmid">31430935</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers11081205</pub-id><pub-id pub-id-type="pmcid">PMC6721629</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Queen</surname><given-names>MM</given-names></name><etal/></person-group><article-title>Breast cancer cells stimulate neutrophils to produce oncostatin M: potential implications for tumor progression</article-title><source>Cancer Res.</source><year>2005</year><volume>65</volume><fpage>8896</fpage><lpage>8904</lpage><pub-id pub-id-type="pmid">16204061</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/0008-5472.CAN-05-1734</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Queen, M. M. et al. Breast cancer cells stimulate neutrophils to produce oncostatin M: potential implications for tumor progression. <italic toggle="yes">Cancer Res.</italic><bold>65</bold>, 8896&#8211;8904 (2005).<pub-id pub-id-type="pmid">16204061</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/0008-5472.CAN-05-1734</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Treffers</surname><given-names>LW</given-names></name><etal/></person-group><article-title>Neutrophils in cancer</article-title><source>Immunol. Rev.</source><year>2016</year><volume>273</volume><fpage>312</fpage><lpage>328</lpage><pub-id pub-id-type="pmid">27558343</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/imr.12444</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Treffers, L. W. et al. Neutrophils in cancer. <italic toggle="yes">Immunol. Rev.</italic><bold>273</bold>, 312&#8211;328 (2016).<pub-id pub-id-type="pmid">27558343</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/imr.12444</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gelsomino</surname><given-names>L</given-names></name><etal/></person-group><article-title>Leptin signaling contributes to aromatase inhibitor resistant breast cancer cell growth and activation of macrophages</article-title><source>Biomolecules</source><year>2020</year><volume>10</volume><fpage>543</fpage><pub-id pub-id-type="pmid">32260113</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/biom10040543</pub-id><pub-id pub-id-type="pmcid">PMC7226081</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Gelsomino, L. et al. Leptin signaling contributes to aromatase inhibitor resistant breast cancer cell growth and activation of macrophages. <italic toggle="yes">Biomolecules</italic><bold>10</bold>, 543 (2020).<pub-id pub-id-type="pmid">32260113</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/biom10040543</pub-id><pub-id pub-id-type="pmcid">PMC7226081</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hughes</surname><given-names>R</given-names></name><etal/></person-group><article-title>Perivascular M2 Macrophages Stimulate Tumor Relapse after Chemotherapy</article-title><source>Cancer Res.</source><year>2015</year><volume>75</volume><fpage>3479</fpage><lpage>3491</lpage><pub-id pub-id-type="pmid">26269531</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/0008-5472.CAN-14-3587</pub-id><pub-id pub-id-type="pmcid">PMC5024531</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Hughes, R. et al. Perivascular M2 Macrophages Stimulate Tumor Relapse after Chemotherapy. <italic toggle="yes">Cancer Res.</italic><bold>75</bold>, 3479&#8211;3491 (2015).<pub-id pub-id-type="pmid">26269531</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/0008-5472.CAN-14-3587</pub-id><pub-id pub-id-type="pmcid">PMC5024531</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Vicente</surname><given-names>JC</given-names></name><etal/></person-group><article-title>Lectin-like transcript-1 (LLT1) expression in oral squamous cell carcinomas: prognostic significance and relationship with the tumor immune microenvironment</article-title><source>Int. J. Mol. Sci.</source><year>2024</year><volume>25</volume><fpage>4314</fpage><pub-id pub-id-type="pmid">38673902</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms25084314</pub-id><pub-id pub-id-type="pmcid">PMC11050533</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">de Vicente, J. C. et al. Lectin-like transcript-1 (LLT1) expression in oral squamous cell carcinomas: prognostic significance and relationship with the tumor immune microenvironment. <italic toggle="yes">Int. J. Mol. Sci.</italic><bold>25</bold>, 4314 (2024).<pub-id pub-id-type="pmid">38673902</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms25084314</pub-id><pub-id pub-id-type="pmcid">PMC11050533</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>S</given-names></name><etal/></person-group><article-title>Single-cell transcriptomics reveal distinct immune-infiltrating phenotypes and macrophage-tumor interaction axes among different lineages of pituitary neuroendocrine tumors</article-title><source>Genome Med.</source><year>2024</year><volume>16</volume><fpage>60</fpage><pub-id pub-id-type="pmid">38658971</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13073-024-01325-4</pub-id><pub-id pub-id-type="pmcid">PMC11040908</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Lin, S. et al. Single-cell transcriptomics reveal distinct immune-infiltrating phenotypes and macrophage-tumor interaction axes among different lineages of pituitary neuroendocrine tumors. <italic toggle="yes">Genome Med.</italic><bold>16</bold>, 60 (2024).<pub-id pub-id-type="pmid">38658971</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13073-024-01325-4</pub-id><pub-id pub-id-type="pmcid">PMC11040908</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tien</surname><given-names>FM</given-names></name><etal/></person-group><article-title>Epigenetic remodeling of the immune landscape in cancer: therapeutic hurdles and opportunities</article-title><source>J. Biomed. Sci.</source><year>2023</year><volume>30</volume><fpage>3</fpage><pub-id pub-id-type="pmid">36627707</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12929-022-00893-0</pub-id><pub-id pub-id-type="pmcid">PMC9832644</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Tien, F. M. et al. Epigenetic remodeling of the immune landscape in cancer: therapeutic hurdles and opportunities. <italic toggle="yes">J. Biomed. Sci.</italic><bold>30</bold>, 3 (2023).<pub-id pub-id-type="pmid">36627707</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12929-022-00893-0</pub-id><pub-id pub-id-type="pmcid">PMC9832644</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yin</surname><given-names>J</given-names></name><etal/></person-group><article-title>Epigenetic modulation of antitumor immunity and immunotherapy response in breast cancer: biological mechanisms and clinical implications</article-title><source>Front. Immunol.</source><year>2023</year><volume>14</volume><fpage>1325615</fpage><pub-id pub-id-type="pmid">38268926</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2023.1325615</pub-id><pub-id pub-id-type="pmcid">PMC10806158</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Yin, J. et al. Epigenetic modulation of antitumor immunity and immunotherapy response in breast cancer: biological mechanisms and clinical implications. <italic toggle="yes">Front. Immunol.</italic><bold>14</bold>, 1325615 (2023).<pub-id pub-id-type="pmid">38268926</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2023.1325615</pub-id><pub-id pub-id-type="pmcid">PMC10806158</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pearson</surname><given-names>JC</given-names></name><name name-style="western"><surname>Lemons</surname><given-names>D</given-names></name><name name-style="western"><surname>McGinnis</surname><given-names>W</given-names></name></person-group><article-title>Modulating Hox gene functions during animal body patterning</article-title><source>Nat. Rev. Genet</source><year>2005</year><volume>6</volume><fpage>893</fpage><lpage>904</lpage><pub-id pub-id-type="pmid">16341070</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrg1726</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Pearson, J. C., Lemons, D. &amp; McGinnis, W. Modulating Hox gene functions during animal body patterning. <italic toggle="yes">Nat. Rev. Genet</italic><bold>6</bold>, 893&#8211;904 (2005).<pub-id pub-id-type="pmid">16341070</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrg1726</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shah</surname><given-names>N</given-names></name><name name-style="western"><surname>Sukumar</surname><given-names>S</given-names></name></person-group><article-title>The Hox genes and their roles in oncogenesis</article-title><source>Nat. Rev. Cancer</source><year>2010</year><volume>10</volume><fpage>361</fpage><lpage>371</lpage><pub-id pub-id-type="pmid">20357775</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrc2826</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Shah, N. &amp; Sukumar, S. The Hox genes and their roles in oncogenesis. <italic toggle="yes">Nat. Rev. Cancer</italic><bold>10</bold>, 361&#8211;371 (2010).<pub-id pub-id-type="pmid">20357775</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrc2826</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bhatlekar</surname><given-names>S</given-names></name><name name-style="western"><surname>Fields</surname><given-names>JZ</given-names></name><name name-style="western"><surname>Boman</surname><given-names>BM</given-names></name></person-group><article-title>HOX genes and their role in the development of human cancers</article-title><source>J. Mol. Med.</source><year>2014</year><volume>92</volume><fpage>811</fpage><lpage>823</lpage><pub-id pub-id-type="pmid">24996520</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00109-014-1181-y</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Bhatlekar, S., Fields, J. Z. &amp; Boman, B. M. HOX genes and their role in the development of human cancers. <italic toggle="yes">J. Mol. Med.</italic><bold>92</bold>, 811&#8211;823 (2014).<pub-id pub-id-type="pmid">24996520</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00109-014-1181-y</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Inamura</surname><given-names>K</given-names></name><etal/></person-group><article-title>HOXB2, an adverse prognostic indicator for stage I lung adenocarcinomas, promotes invasion by transcriptional regulation of metastasis-related genes in HOP-62 non-small cell lung cancer cells</article-title><source>Anticancer Res.</source><year>2008</year><volume>28</volume><fpage>2121</fpage><lpage>2127</lpage><pub-id pub-id-type="pmid">18751384</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Inamura, K. et al. HOXB2, an adverse prognostic indicator for stage I lung adenocarcinomas, promotes invasion by transcriptional regulation of metastasis-related genes in HOP-62 non-small cell lung cancer cells. <italic toggle="yes">Anticancer Res.</italic><bold>28</bold>, 2121&#8211;2127 (2008).<pub-id pub-id-type="pmid">18751384</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gonzalez-Herrera</surname><given-names>A</given-names></name><etal/></person-group><article-title>Increased expression of HOXB2 and HOXB13 proteins is associated with HPV infection and cervical cancer progression</article-title><source>Asian Pac. J. Cancer Prev.</source><year>2015</year><volume>16</volume><fpage>1349</fpage><lpage>1353</lpage><pub-id pub-id-type="pmid">25743797</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7314/apjcp.2015.16.4.1349</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Gonzalez-Herrera, A. et al. Increased expression of HOXB2 and HOXB13 proteins is associated with HPV infection and cervical cancer progression. <italic toggle="yes">Asian Pac. J. Cancer Prev.</italic><bold>16</bold>, 1349&#8211;1353 (2015).<pub-id pub-id-type="pmid">25743797</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7314/apjcp.2015.16.4.1349</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>F</given-names></name><etal/></person-group><article-title>Epigenetic induction of tumor stemness via the lipopolysaccharide-TET3-HOXB2 signaling axis in esophageal squamous cell carcinoma</article-title><source>Cell Commun. Signal</source><year>2020</year><volume>18</volume><fpage>17</fpage><pub-id pub-id-type="pmid">32014008</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12964-020-0510-8</pub-id><pub-id pub-id-type="pmcid">PMC6998358</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Xu, F. et al. Epigenetic induction of tumor stemness via the lipopolysaccharide-TET3-HOXB2 signaling axis in esophageal squamous cell carcinoma. <italic toggle="yes">Cell Commun. Signal</italic><bold>18</bold>, 17 (2020).<pub-id pub-id-type="pmid">32014008</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12964-020-0510-8</pub-id><pub-id pub-id-type="pmcid">PMC6998358</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dongre</surname><given-names>A</given-names></name><name name-style="western"><surname>Weinberg</surname><given-names>RA</given-names></name></person-group><article-title>New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer</article-title><source>Nat. Rev. Mol. Cell Biol.</source><year>2019</year><volume>20</volume><fpage>69</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">30459476</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41580-018-0080-4</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Dongre, A. &amp; Weinberg, R. A. New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. <italic toggle="yes">Nat. Rev. Mol. Cell Biol.</italic><bold>20</bold>, 69&#8211;84 (2019).<pub-id pub-id-type="pmid">30459476</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41580-018-0080-4</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oh</surname><given-names>JH</given-names></name><etal/></person-group><article-title>The homeoprotein HOXB2 limits triple-negative breast carcinogenesis via extracellular matrix remodeling</article-title><source>Int J. Biol. Sci.</source><year>2024</year><volume>20</volume><fpage>1045</fpage><lpage>1063</lpage><pub-id pub-id-type="pmid">38322121</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7150/ijbs.88837</pub-id><pub-id pub-id-type="pmcid">PMC10845296</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Oh, J. H. et al. The homeoprotein HOXB2 limits triple-negative breast carcinogenesis via extracellular matrix remodeling. <italic toggle="yes">Int J. Biol. Sci.</italic><bold>20</bold>, 1045&#8211;1063 (2024).<pub-id pub-id-type="pmid">38322121</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7150/ijbs.88837</pub-id><pub-id pub-id-type="pmcid">PMC10845296</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>HY</given-names></name><name name-style="western"><surname>Pan</surname><given-names>SS</given-names></name></person-group><article-title>MiR-202-5p suppressed cell proliferation, migration and invasion in ovarian cancer via regulating HOXB2</article-title><source>Eur. Rev. Med. Pharm. Sci.</source><year>2020</year><volume>24</volume><fpage>2256</fpage><lpage>2263</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.26355/eurrev_202003_20491</pub-id><pub-id pub-id-type="pmid">32196576</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Yu, H. Y. &amp; Pan, S. S. MiR-202-5p suppressed cell proliferation, migration and invasion in ovarian cancer via regulating HOXB2. <italic toggle="yes">Eur. Rev. Med. Pharm. Sci.</italic><bold>24</bold>, 2256&#8211;2263 (2020).<pub-id pub-id-type="doi" assigning-authority="pmc">10.26355/eurrev_202003_20491</pub-id><pub-id pub-id-type="pmid">32196576</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boimel</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Cruz</surname><given-names>C</given-names></name><name name-style="western"><surname>Segall</surname><given-names>JE</given-names></name></person-group><article-title>A functional in vivo screen for regulators of tumor progression identifies HOXB2 as a regulator of tumor growth in breast cancer</article-title><source>Genomics</source><year>2011</year><volume>98</volume><fpage>164</fpage><lpage>172</lpage><pub-id pub-id-type="pmid">21672623</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ygeno.2011.05.011</pub-id><pub-id pub-id-type="pmcid">PMC3165059</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Boimel, P. J., Cruz, C. &amp; Segall, J. E. A functional in vivo screen for regulators of tumor progression identifies HOXB2 as a regulator of tumor growth in breast cancer. <italic toggle="yes">Genomics</italic><bold>98</bold>, 164&#8211;172 (2011).<pub-id pub-id-type="pmid">21672623</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ygeno.2011.05.011</pub-id><pub-id pub-id-type="pmcid">PMC3165059</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bl&#252;cher</surname><given-names>C</given-names></name><name name-style="western"><surname>Stadler</surname><given-names>SC</given-names></name></person-group><article-title>Obesity and breast cancer: current insights on the role of fatty acids and lipid metabolism in promoting breast cancer growth and progression</article-title><source>Front Endocrinol.</source><year>2017</year><volume>8</volume><fpage>293</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fendo.2017.00293</pub-id><pub-id pub-id-type="pmcid">PMC5670108</pub-id><pub-id pub-id-type="pmid">29163362</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Bl&#252;cher, C. &amp; Stadler, S. C. Obesity and breast cancer: current insights on the role of fatty acids and lipid metabolism in promoting breast cancer growth and progression. <italic toggle="yes">Front Endocrinol.</italic><bold>8</bold>, 293 (2017).<pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fendo.2017.00293</pub-id><pub-id pub-id-type="pmcid">PMC5670108</pub-id><pub-id pub-id-type="pmid">29163362</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Madak-Erdogan</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Free fatty acids rewire cancer metabolism in obesity-associated breast cancer via estrogen receptor and mTOR signaling</article-title><source>Cancer Res.</source><year>2019</year><volume>79</volume><fpage>2494</fpage><lpage>2510</lpage><pub-id pub-id-type="pmid">30862719</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/0008-5472.CAN-18-2849</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Madak-Erdogan, Z. et al. Free fatty acids rewire cancer metabolism in obesity-associated breast cancer via estrogen receptor and mTOR signaling. <italic toggle="yes">Cancer Res.</italic><bold>79</bold>, 2494&#8211;2510 (2019).<pub-id pub-id-type="pmid">30862719</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/0008-5472.CAN-18-2849</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>George Warren</surname><given-names>W</given-names></name><etal/></person-group><article-title>The emerging role of fatty acid binding protein 5 (FABP5) in cancers</article-title><source>Drug Discov. Today</source><year>2023</year><volume>28</volume><fpage>103628</fpage><pub-id pub-id-type="pmid">37230284</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.drudis.2023.103628</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">George Warren, W. et al. The emerging role of fatty acid binding protein 5 (FABP5) in cancers. <italic toggle="yes">Drug Discov. Today</italic><bold>28</bold>, 103628 (2023).<pub-id pub-id-type="pmid">37230284</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.drudis.2023.103628</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Cell biology of IL-7, a key lymphotrophin</article-title><source>Cytokine Growth Factor Rev.</source><year>2005</year><volume>16</volume><fpage>513</fpage><lpage>533</lpage><pub-id pub-id-type="pmid">15996891</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cytogfr.2005.05.004</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Jiang, Q. et al. Cell biology of IL-7, a key lymphotrophin. <italic toggle="yes">Cytokine Growth Factor Rev.</italic><bold>16</bold>, 513&#8211;533 (2005).<pub-id pub-id-type="pmid">15996891</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cytogfr.2005.05.004</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iwata</surname><given-names>M</given-names></name><etal/></person-group><article-title>Functional interleukin-7 receptors (IL-7Rs) are expressed by marrow stromal cells: binding of IL-7 increases levels of IL-6 mRNA and secreted protein</article-title><source>Blood</source><year>2002</year><volume>100</volume><fpage>1318</fpage><lpage>1325</lpage><pub-id pub-id-type="pmid">12149213</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/blood-2002-01-0062</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Iwata, M. et al. Functional interleukin-7 receptors (IL-7Rs) are expressed by marrow stromal cells: binding of IL-7 increases levels of IL-6 mRNA and secreted protein. <italic toggle="yes">Blood</italic><bold>100</bold>, 1318&#8211;1325 (2002).<pub-id pub-id-type="pmid">12149213</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/blood-2002-01-0062</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Al-Rawi</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Aberrant expression of interleukin-7 (IL-7) and its signalling complex in human breast cancer</article-title><source>Eur. J. Cancer</source><year>2004</year><volume>40</volume><fpage>494</fpage><lpage>502</lpage><pub-id pub-id-type="pmid">14962714</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejca.2003.10.016</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Al-Rawi, M. A. et al. Aberrant expression of interleukin-7 (IL-7) and its signalling complex in human breast cancer. <italic toggle="yes">Eur. J. Cancer</italic><bold>40</bold>, 494&#8211;502 (2004).<pub-id pub-id-type="pmid">14962714</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejca.2003.10.016</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fernandez-Botran</surname><given-names>R</given-names></name></person-group><article-title>Soluble cytokine receptors: basic immunology and clinical applications</article-title><source>Crit. Rev. Clin. Lab Sci.</source><year>1999</year><volume>36</volume><fpage>165</fpage><lpage>224</lpage><pub-id pub-id-type="pmid">10407682</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/10408369991239196</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">Fernandez-Botran, R. Soluble cytokine receptors: basic immunology and clinical applications. <italic toggle="yes">Crit. Rev. Clin. Lab Sci.</italic><bold>36</bold>, 165&#8211;224 (1999).<pub-id pub-id-type="pmid">10407682</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/10408369991239196</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fernandez-Botran</surname><given-names>R</given-names></name><name name-style="western"><surname>Crespo</surname><given-names>FA</given-names></name><name name-style="western"><surname>Sun</surname><given-names>X</given-names></name></person-group><article-title>Soluble cytokine receptors in biological therapy</article-title><source>Expert Opin. Biol. Ther.</source><year>2002</year><volume>2</volume><fpage>585</fpage><lpage>605</lpage><pub-id pub-id-type="pmid">12171504</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1517/14712598.2.6.585</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Fernandez-Botran, R., Crespo, F. A. &amp; Sun, X. Soluble cytokine receptors in biological therapy. <italic toggle="yes">Expert Opin. Biol. Ther.</italic><bold>2</bold>, 585&#8211;605 (2002).<pub-id pub-id-type="pmid">12171504</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1517/14712598.2.6.585</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lundstr&#246;m</surname><given-names>W</given-names></name><etal/></person-group><article-title>Soluble IL7R&#945; potentiates IL-7 bioactivity and promotes autoimmunity</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2013</year><volume>110</volume><fpage>E1761</fpage><lpage>E1770</lpage><pub-id pub-id-type="pmid">23610432</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1222303110</pub-id><pub-id pub-id-type="pmcid">PMC3651437</pub-id></element-citation><mixed-citation id="mc-CR41" publication-type="journal">Lundstr&#246;m, W. et al. Soluble IL7R&#945; potentiates IL-7 bioactivity and promotes autoimmunity. <italic toggle="yes">Proc. Natl. Acad. Sci. USA</italic><bold>110</bold>, E1761&#8211;E1770 (2013).<pub-id pub-id-type="pmid">23610432</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1222303110</pub-id><pub-id pub-id-type="pmcid">PMC3651437</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>B</given-names></name><name name-style="western"><surname>Hong</surname><given-names>C</given-names></name></person-group><article-title>The role of soluble common gamma chain in autoimmune disease</article-title><source>Anat. Cell Biol.</source><year>2015</year><volume>48</volume><fpage>10</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">25806117</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5115/acb.2015.48.1.10</pub-id><pub-id pub-id-type="pmcid">PMC4371176</pub-id></element-citation><mixed-citation id="mc-CR42" publication-type="journal">Lee, B. &amp; Hong, C. The role of soluble common gamma chain in autoimmune disease. <italic toggle="yes">Anat. Cell Biol.</italic><bold>48</bold>, 10&#8211;15 (2015).<pub-id pub-id-type="pmid">25806117</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5115/acb.2015.48.1.10</pub-id><pub-id pub-id-type="pmcid">PMC4371176</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lundmark</surname><given-names>F</given-names></name><etal/></person-group><article-title>Variation in interleukin 7 receptor alpha chain (IL7R) influences risk of multiple sclerosis</article-title><source>Nat. Genet.</source><year>2007</year><volume>39</volume><fpage>1108</fpage><lpage>1113</lpage><pub-id pub-id-type="pmid">17660816</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ng2106</pub-id></element-citation><mixed-citation id="mc-CR43" publication-type="journal">Lundmark, F. et al. Variation in interleukin 7 receptor alpha chain (IL7R) influences risk of multiple sclerosis. <italic toggle="yes">Nat. Genet.</italic><bold>39</bold>, 1108&#8211;1113 (2007).<pub-id pub-id-type="pmid">17660816</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ng2106</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Todd</surname><given-names>JA</given-names></name><etal/></person-group><article-title>Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes</article-title><source>Nat. Genet.</source><year>2007</year><volume>39</volume><fpage>857</fpage><lpage>864</lpage><pub-id pub-id-type="pmid">17554260</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ng2068</pub-id><pub-id pub-id-type="pmcid">PMC2492393</pub-id></element-citation><mixed-citation id="mc-CR44" publication-type="journal">Todd, J. A. et al. Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. <italic toggle="yes">Nat. Genet.</italic><bold>39</bold>, 857&#8211;864 (2007).<pub-id pub-id-type="pmid">17554260</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ng2068</pub-id><pub-id pub-id-type="pmcid">PMC2492393</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McKay</surname><given-names>FC</given-names></name><etal/></person-group><article-title>Haplotypes of the interleukin 7 receptor alpha gene are correlated with altered expression in whole blood cells in multiple sclerosis</article-title><source>Genes Immun.</source><year>2008</year><volume>9</volume><fpage>1</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">17928869</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/sj.gene.6364436</pub-id></element-citation><mixed-citation id="mc-CR45" publication-type="journal">McKay, F. C. et al. Haplotypes of the interleukin 7 receptor alpha gene are correlated with altered expression in whole blood cells in multiple sclerosis. <italic toggle="yes">Genes Immun.</italic><bold>9</bold>, 1&#8211;6 (2008).<pub-id pub-id-type="pmid">17928869</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/sj.gene.6364436</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Crawley</surname><given-names>AM</given-names></name><name name-style="western"><surname>Faucher</surname><given-names>S</given-names></name><name name-style="western"><surname>Angel</surname><given-names>JB</given-names></name></person-group><article-title>Soluble IL-7R alpha (sCD127) inhibits IL-7 activity and is increased in HIV infection</article-title><source>J. Immunol.</source><year>2010</year><volume>184</volume><fpage>4679</fpage><lpage>4687</lpage><pub-id pub-id-type="pmid">20304824</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.0903758</pub-id></element-citation><mixed-citation id="mc-CR46" publication-type="journal">Crawley, A. M., Faucher, S. &amp; Angel, J. B. Soluble IL-7R alpha (sCD127) inhibits IL-7 activity and is increased in HIV infection. <italic toggle="yes">J. Immunol.</italic><bold>184</bold>, 4679&#8211;4687 (2010).<pub-id pub-id-type="pmid">20304824</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.0903758</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>SL</given-names></name><etal/></person-group><article-title>p27KIP1 is involved in ERK1/2-mediated MMP-9 expression via the activation of NF-&#954;B binding in the IL-7-induced migration and invasion of 5637 cells</article-title><source>Int J. Oncol.</source><year>2014</year><volume>44</volume><fpage>1349</fpage><lpage>1356</lpage><pub-id pub-id-type="pmid">24504262</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/ijo.2014.2290</pub-id></element-citation><mixed-citation id="mc-CR47" publication-type="journal">Park, S. L. et al. p27KIP1 is involved in ERK1/2-mediated MMP-9 expression via the activation of NF-&#954;B binding in the IL-7-induced migration and invasion of 5637 cells. <italic toggle="yes">Int J. Oncol.</italic><bold>44</bold>, 1349&#8211;1356 (2014).<pub-id pub-id-type="pmid">24504262</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/ijo.2014.2290</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>D</given-names></name><etal/></person-group><article-title>Interleukin-7 biology and its effects on immune cells: mediator of generation, differentiation, survival, and homeostasis</article-title><source>Front Immunol.</source><year>2021</year><volume>12</volume><fpage>747324</fpage><pub-id pub-id-type="pmid">34925323</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2021.747324</pub-id><pub-id pub-id-type="pmcid">PMC8674869</pub-id></element-citation><mixed-citation id="mc-CR48" publication-type="journal">Chen, D. et al. Interleukin-7 biology and its effects on immune cells: mediator of generation, differentiation, survival, and homeostasis. <italic toggle="yes">Front Immunol.</italic><bold>12</bold>, 747324 (2021).<pub-id pub-id-type="pmid">34925323</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2021.747324</pub-id><pub-id pub-id-type="pmcid">PMC8674869</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Delgado-Martin</surname><given-names>C</given-names></name><etal/></person-group><article-title>JAK/STAT pathway inhibition overcomes IL7-induced glucocorticoid resistance in a subset of human T-cell acute lymphoblastic leukemias</article-title><source>Leukemia</source><year>2017</year><volume>31</volume><fpage>2568</fpage><lpage>2576</lpage><pub-id pub-id-type="pmid">28484265</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/leu.2017.136</pub-id><pub-id pub-id-type="pmcid">PMC5729333</pub-id></element-citation><mixed-citation id="mc-CR49" publication-type="journal">Delgado-Martin, C. et al. JAK/STAT pathway inhibition overcomes IL7-induced glucocorticoid resistance in a subset of human T-cell acute lymphoblastic leukemias. <italic toggle="yes">Leukemia</italic><bold>31</bold>, 2568&#8211;2576 (2017).<pub-id pub-id-type="pmid">28484265</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/leu.2017.136</pub-id><pub-id pub-id-type="pmcid">PMC5729333</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ribeiro</surname><given-names>D</given-names></name><etal/></person-group><article-title>STAT5 is essential for IL-7-mediated viability, growth, and proliferation of T-cell acute lymphoblastic leukemia cells</article-title><source>Blood Adv.</source><year>2018</year><volume>2</volume><fpage>2199</fpage><lpage>2213</lpage><pub-id pub-id-type="pmid">30185437</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/bloodadvances.2018021063</pub-id><pub-id pub-id-type="pmcid">PMC6134214</pub-id></element-citation><mixed-citation id="mc-CR50" publication-type="journal">Ribeiro, D. et al. STAT5 is essential for IL-7-mediated viability, growth, and proliferation of T-cell acute lymphoblastic leukemia cells. <italic toggle="yes">Blood Adv.</italic><bold>2</bold>, 2199&#8211;2213 (2018).<pub-id pub-id-type="pmid">30185437</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/bloodadvances.2018021063</pub-id><pub-id pub-id-type="pmcid">PMC6134214</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barata</surname><given-names>JT</given-names></name><etal/></person-group><article-title>Activation of PI3K is indispensable for interleukin 7-mediated viability, proliferation, glucose use, and growth of T cell acute lymphoblastic leukemia cells</article-title><source>J. Exp. Med</source><year>2004</year><volume>200</volume><fpage>659</fpage><lpage>669</lpage><pub-id pub-id-type="pmid">15353558</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1084/jem.20040789</pub-id><pub-id pub-id-type="pmcid">PMC2212738</pub-id></element-citation><mixed-citation id="mc-CR51" publication-type="journal">Barata, J. T. et al. Activation of PI3K is indispensable for interleukin 7-mediated viability, proliferation, glucose use, and growth of T cell acute lymphoblastic leukemia cells. <italic toggle="yes">J. Exp. Med</italic><bold>200</bold>, 659&#8211;669 (2004).<pub-id pub-id-type="pmid">15353558</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1084/jem.20040789</pub-id><pub-id pub-id-type="pmcid">PMC2212738</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shum</surname><given-names>T</given-names></name><etal/></person-group><article-title>Constitutive signaling from an engineered IL7 receptor promotes durable tumor elimination by tumor-redirected T cells</article-title><source>Cancer Discov.</source><year>2017</year><volume>7</volume><fpage>1238</fpage><lpage>1247</lpage><pub-id pub-id-type="pmid">28830878</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/2159-8290.CD-17-0538</pub-id><pub-id pub-id-type="pmcid">PMC5669830</pub-id></element-citation><mixed-citation id="mc-CR52" publication-type="journal">Shum, T. et al. Constitutive signaling from an engineered IL7 receptor promotes durable tumor elimination by tumor-redirected T cells. <italic toggle="yes">Cancer Discov.</italic><bold>7</bold>, 1238&#8211;1247 (2017).<pub-id pub-id-type="pmid">28830878</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/2159-8290.CD-17-0538</pub-id><pub-id pub-id-type="pmcid">PMC5669830</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Engineered IL-7 receptor enhances the therapeutic effect of AXL-CAR-T cells on triple-negative breast cancer</article-title><source>Biomed. Res Int</source><year>2020</year><volume>2020</volume><fpage>4795171</fpage><pub-id pub-id-type="pmid">31998790</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2020/4795171</pub-id><pub-id pub-id-type="pmcid">PMC6970498</pub-id></element-citation><mixed-citation id="mc-CR53" publication-type="journal">Zhao, Z. et al. Engineered IL-7 receptor enhances the therapeutic effect of AXL-CAR-T cells on triple-negative breast cancer. <italic toggle="yes">Biomed. Res Int</italic><bold>2020</bold>, 4795171 (2020).<pub-id pub-id-type="pmid">31998790</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2020/4795171</pub-id><pub-id pub-id-type="pmcid">PMC6970498</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>B</given-names></name><etal/></person-group><article-title>B7-H3 specific T cells with chimeric antigen receptor and decoy PD-1 receptors eradicate established solid human tumors in mouse models</article-title><source>Oncoimmunology</source><year>2020</year><volume>9</volume><fpage>1684127</fpage><pub-id pub-id-type="pmid">32002297</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/2162402X.2019.1684127</pub-id><pub-id pub-id-type="pmcid">PMC6959446</pub-id></element-citation><mixed-citation id="mc-CR54" publication-type="journal">Huang, B. et al. B7-H3 specific T cells with chimeric antigen receptor and decoy PD-1 receptors eradicate established solid human tumors in mouse models. <italic toggle="yes">Oncoimmunology</italic><bold>9</bold>, 1684127 (2020).<pub-id pub-id-type="pmid">32002297</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/2162402X.2019.1684127</pub-id><pub-id pub-id-type="pmcid">PMC6959446</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Noh</surname><given-names>KE</given-names></name><etal/></person-group><article-title>TGF-&#946;/IL-7 Chimeric switch receptor-expressing CAR-T cells inhibit recurrence of CD19-positive B cell lymphoma</article-title><source>Int. J. Mol. Sci.</source><year>2022</year><volume>22</volume><fpage>8706</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms22168706</pub-id><pub-id pub-id-type="pmcid">PMC8395772</pub-id><pub-id pub-id-type="pmid">34445415</pub-id></element-citation><mixed-citation id="mc-CR55" publication-type="journal">Noh, K. E. et al. TGF-&#946;/IL-7 Chimeric switch receptor-expressing CAR-T cells inhibit recurrence of CD19-positive B cell lymphoma. <italic toggle="yes">Int. J. Mol. Sci.</italic><bold>22</bold>, 8706 (2022).<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms22168706</pub-id><pub-id pub-id-type="pmcid">PMC8395772</pub-id><pub-id pub-id-type="pmid">34445415</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yasunaga</surname><given-names>M</given-names></name></person-group><article-title>Antibody therapeutics and immunoregulation in cancer and autoimmune disease</article-title><source>Semin Cancer Biol.</source><year>2020</year><volume>64</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">31181267</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.semcancer.2019.06.001</pub-id></element-citation><mixed-citation id="mc-CR56" publication-type="journal">Yasunaga, M. Antibody therapeutics and immunoregulation in cancer and autoimmune disease. <italic toggle="yes">Semin Cancer Biol.</italic><bold>64</bold>, 1&#8211;12 (2020).<pub-id pub-id-type="pmid">31181267</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.semcancer.2019.06.001</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Penaranda</surname><given-names>C</given-names></name><etal/></person-group><article-title>IL-7 receptor blockade reverses autoimmune diabetes by promoting inhibition of effector/memory T cells</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2012</year><volume>109</volume><fpage>12668</fpage><lpage>12673</lpage><pub-id pub-id-type="pmid">22733744</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1203692109</pub-id><pub-id pub-id-type="pmcid">PMC3411948</pub-id></element-citation><mixed-citation id="mc-CR57" publication-type="journal">Penaranda, C. et al. IL-7 receptor blockade reverses autoimmune diabetes by promoting inhibition of effector/memory T cells. <italic toggle="yes">Proc. Natl. Acad. Sci. USA</italic><bold>109</bold>, 12668&#8211;12673 (2012).<pub-id pub-id-type="pmid">22733744</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1203692109</pub-id><pub-id pub-id-type="pmcid">PMC3411948</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hartgring</surname><given-names>SA</given-names></name><etal/></person-group><article-title>Blockade of the interleukin-7 receptor inhibits collagen-induced arthritis and is associated with reduction of T cell activity and proinflammatory mediators</article-title><source>Arthritis Rheum.</source><year>2010</year><volume>62</volume><fpage>2716</fpage><lpage>2725</lpage><pub-id pub-id-type="pmid">20499386</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/art.27578</pub-id></element-citation><mixed-citation id="mc-CR58" publication-type="journal">Hartgring, S. A. et al. Blockade of the interleukin-7 receptor inhibits collagen-induced arthritis and is associated with reduction of T cell activity and proinflammatory mediators. <italic toggle="yes">Arthritis Rheum.</italic><bold>62</bold>, 2716&#8211;2725 (2010).<pub-id pub-id-type="pmid">20499386</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/art.27578</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR59"><label>59.</label><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yasunaga</surname><given-names>M</given-names></name><name name-style="western"><surname>Manabe</surname><given-names>S</given-names></name><name name-style="western"><surname>Matsumura</surname><given-names>Y</given-names></name></person-group><article-title>Immunoregulation by IL-7R-targeting antibody-drug conjugates: overcoming steroid-resistance in cancer and autoimmune disease</article-title><source>Sci. Rep.</source><year>2017</year><volume>7</volume><fpage>10735</fpage><pub-id pub-id-type="pmid">28878234</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-017-11255-4</pub-id><pub-id pub-id-type="pmcid">PMC5587554</pub-id></element-citation><mixed-citation id="mc-CR59" publication-type="journal">Yasunaga, M., Manabe, S. &amp; Matsumura, Y. Immunoregulation by IL-7R-targeting antibody-drug conjugates: overcoming steroid-resistance in cancer and autoimmune disease. <italic toggle="yes">Sci. Rep.</italic><bold>7</bold>, 10735 (2017).<pub-id pub-id-type="pmid">28878234</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-017-11255-4</pub-id><pub-id pub-id-type="pmcid">PMC5587554</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR60"><label>60.</label><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Akkapeddi</surname><given-names>P</given-names></name><etal/></person-group><article-title>A fully human anti-IL-7R&#945; antibody promotes antitumor activity against T-cell acute lymphoblastic leukemia</article-title><source>Leukemia</source><year>2019</year><volume>33</volume><fpage>2155</fpage><lpage>2168</lpage><pub-id pub-id-type="pmid">30850736</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41375-019-0434-8</pub-id><pub-id pub-id-type="pmcid">PMC6733707</pub-id></element-citation><mixed-citation id="mc-CR60" publication-type="journal">Akkapeddi, P. et al. A fully human anti-IL-7R&#945; antibody promotes antitumor activity against T-cell acute lymphoblastic leukemia. <italic toggle="yes">Leukemia</italic><bold>33</bold>, 2155&#8211;2168 (2019).<pub-id pub-id-type="pmid">30850736</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41375-019-0434-8</pub-id><pub-id pub-id-type="pmcid">PMC6733707</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR61"><label>61.</label><citation-alternatives><element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Senkevitch</surname><given-names>E</given-names></name><etal/></person-group><article-title>Inhibiting Janus Kinase 1 and BCL-2 to treat T cell acute lymphoblastic leukemia with IL7-R&#945; mutations</article-title><source>Oncotarget</source><year>2018</year><volume>9</volume><fpage>22605</fpage><lpage>22617</lpage><pub-id pub-id-type="pmid">29854301</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18632/oncotarget.25194</pub-id><pub-id pub-id-type="pmcid">PMC5978251</pub-id></element-citation><mixed-citation id="mc-CR61" publication-type="journal">Senkevitch, E. et al. Inhibiting Janus Kinase 1 and BCL-2 to treat T cell acute lymphoblastic leukemia with IL7-R&#945; mutations. <italic toggle="yes">Oncotarget</italic><bold>9</bold>, 22605&#8211;22617 (2018).<pub-id pub-id-type="pmid">29854301</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18632/oncotarget.25194</pub-id><pub-id pub-id-type="pmcid">PMC5978251</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR62"><label>62.</label><citation-alternatives><element-citation id="ec-CR62" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maude</surname><given-names>SL</given-names></name><etal/></person-group><article-title>Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia</article-title><source>Blood</source><year>2012</year><volume>120</volume><fpage>3510</fpage><lpage>3518</lpage><pub-id pub-id-type="pmid">22955920</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/blood-2012-03-415448</pub-id><pub-id pub-id-type="pmcid">PMC3482861</pub-id></element-citation><mixed-citation id="mc-CR62" publication-type="journal">Maude, S. L. et al. Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia. <italic toggle="yes">Blood</italic><bold>120</bold>, 3510&#8211;3518 (2012).<pub-id pub-id-type="pmid">22955920</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/blood-2012-03-415448</pub-id><pub-id pub-id-type="pmcid">PMC3482861</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR63"><label>63.</label><citation-alternatives><element-citation id="ec-CR63" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oda</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Soluble lactose-binding lectin from rat intestine with two different carbohydrate-binding domains in the same peptide chain</article-title><source>J. Biol. Chem.</source><year>1993</year><volume>268</volume><fpage>5929</fpage><lpage>5939</lpage><pub-id pub-id-type="pmid">8449956</pub-id></element-citation><mixed-citation id="mc-CR63" publication-type="journal">Oda, Y. et al. Soluble lactose-binding lectin from rat intestine with two different carbohydrate-binding domains in the same peptide chain. <italic toggle="yes">J. Biol. Chem.</italic><bold>268</bold>, 5929&#8211;5939 (1993).<pub-id pub-id-type="pmid">8449956</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR64"><label>64.</label><citation-alternatives><element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barondes</surname><given-names>SH</given-names></name><etal/></person-group><article-title>Galectins. Structure and function of a large family of animal lectins</article-title><source>J. Biol. Chem.</source><year>1994</year><volume>269</volume><fpage>20807</fpage><lpage>20810</lpage><pub-id pub-id-type="pmid">8063692</pub-id></element-citation><mixed-citation id="mc-CR64" publication-type="journal">Barondes, S. H. et al. Galectins. Structure and function of a large family of animal lectins. <italic toggle="yes">J. Biol. Chem.</italic><bold>269</bold>, 20807&#8211;20810 (1994).<pub-id pub-id-type="pmid">8063692</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR65"><label>65.</label><citation-alternatives><element-citation id="ec-CR65" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yasinska</surname><given-names>IM</given-names></name><etal/></person-group><article-title>The Tim-3-Galectin-9 Pathway and Its Regulatory Mechanisms in Human Breast Cancer</article-title><source>Front. Immunol.</source><year>2019</year><volume>10</volume><fpage>1594</fpage><pub-id pub-id-type="pmid">31354733</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2019.01594</pub-id><pub-id pub-id-type="pmcid">PMC6637653</pub-id></element-citation><mixed-citation id="mc-CR65" publication-type="journal">Yasinska, I. M. et al. The Tim-3-Galectin-9 Pathway and Its Regulatory Mechanisms in Human Breast Cancer. <italic toggle="yes">Front. Immunol.</italic><bold>10</bold>, 1594 (2019).<pub-id pub-id-type="pmid">31354733</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2019.01594</pub-id><pub-id pub-id-type="pmcid">PMC6637653</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR66"><label>66.</label><citation-alternatives><element-citation id="ec-CR66" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Z</given-names></name><etal/></person-group><article-title>The role of Tim-3/Galectin-9 pathway in T-cell function and prognosis of patients with human papilloma virus-associated cervical carcinoma</article-title><source>Faseb J.</source><year>2021</year><volume>35</volume><fpage>e21401</fpage><pub-id pub-id-type="pmid">33559190</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1096/fj.202000528RR</pub-id><pub-id pub-id-type="pmcid">PMC12266312</pub-id></element-citation><mixed-citation id="mc-CR66" publication-type="journal">Chen, Z. et al. The role of Tim-3/Galectin-9 pathway in T-cell function and prognosis of patients with human papilloma virus-associated cervical carcinoma. <italic toggle="yes">Faseb J.</italic><bold>35</bold>, e21401 (2021).<pub-id pub-id-type="pmid">33559190</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1096/fj.202000528RR</pub-id><pub-id pub-id-type="pmcid">PMC12266312</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR67"><label>67.</label><citation-alternatives><element-citation id="ec-CR67" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seifert</surname><given-names>AM</given-names></name><etal/></person-group><article-title>Detection of pancreatic ductal adenocarcinoma with galectin-9 serum levels</article-title><source>Oncogene</source><year>2020</year><volume>39</volume><fpage>3102</fpage><lpage>3113</lpage><pub-id pub-id-type="pmid">32055023</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41388-020-1186-7</pub-id><pub-id pub-id-type="pmcid">PMC7142017</pub-id></element-citation><mixed-citation id="mc-CR67" publication-type="journal">Seifert, A. M. et al. Detection of pancreatic ductal adenocarcinoma with galectin-9 serum levels. <italic toggle="yes">Oncogene</italic><bold>39</bold>, 3102&#8211;3113 (2020).<pub-id pub-id-type="pmid">32055023</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41388-020-1186-7</pub-id><pub-id pub-id-type="pmcid">PMC7142017</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR68"><label>68.</label><citation-alternatives><element-citation id="ec-CR68" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yuan</surname><given-names>F</given-names></name><etal/></person-group><article-title>Molecular and clinical characterization of Galectin-9 in glioma through 1027 samples</article-title><source>J. Cell Physiol.</source><year>2020</year><volume>235</volume><fpage>4326</fpage><lpage>4334</lpage><pub-id pub-id-type="pmid">31609000</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jcp.29309</pub-id><pub-id pub-id-type="pmcid">PMC7028024</pub-id></element-citation><mixed-citation id="mc-CR68" publication-type="journal">Yuan, F. et al. Molecular and clinical characterization of Galectin-9 in glioma through 1027 samples. <italic toggle="yes">J. Cell Physiol.</italic><bold>235</bold>, 4326&#8211;4334 (2020).<pub-id pub-id-type="pmid">31609000</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jcp.29309</pub-id><pub-id pub-id-type="pmcid">PMC7028024</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR69"><label>69.</label><citation-alternatives><element-citation id="ec-CR69" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nakajima</surname><given-names>R</given-names></name><etal/></person-group><article-title>Possible therapeutic applicability of galectin-9 in cutaneous T-cell lymphoma</article-title><source>J. Dermatol Sci.</source><year>2019</year><volume>96</volume><fpage>134</fpage><lpage>142</lpage><pub-id pub-id-type="pmid">31787505</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jdermsci.2019.09.004</pub-id></element-citation><mixed-citation id="mc-CR69" publication-type="journal">Nakajima, R. et al. Possible therapeutic applicability of galectin-9 in cutaneous T-cell lymphoma. <italic toggle="yes">J. Dermatol Sci.</italic><bold>96</bold>, 134&#8211;142 (2019).<pub-id pub-id-type="pmid">31787505</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jdermsci.2019.09.004</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR70"><label>70.</label><citation-alternatives><element-citation id="ec-CR70" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wdowiak</surname><given-names>K</given-names></name><etal/></person-group><article-title>Increased serum levels of Galectin-9 in patients with chronic lymphocytic leukemia</article-title><source>Oncol. Lett.</source><year>2019</year><volume>17</volume><fpage>1019</fpage><lpage>1029</lpage><pub-id pub-id-type="pmid">30655861</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/ol.2018.9656</pub-id><pub-id pub-id-type="pmcid">PMC6313089</pub-id></element-citation><mixed-citation id="mc-CR70" publication-type="journal">Wdowiak, K. et al. Increased serum levels of Galectin-9 in patients with chronic lymphocytic leukemia. <italic toggle="yes">Oncol. Lett.</italic><bold>17</bold>, 1019&#8211;1029 (2019).<pub-id pub-id-type="pmid">30655861</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/ol.2018.9656</pub-id><pub-id pub-id-type="pmcid">PMC6313089</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR71"><label>71.</label><citation-alternatives><element-citation id="ec-CR71" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>C</given-names></name><etal/></person-group><article-title>Galectin-9-CD44 interaction enhances stability and function of adaptive regulatory T cells</article-title><source>Immunity</source><year>2014</year><volume>41</volume><fpage>270</fpage><lpage>282</lpage><pub-id pub-id-type="pmid">25065622</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.immuni.2014.06.011</pub-id><pub-id pub-id-type="pmcid">PMC4219323</pub-id></element-citation><mixed-citation id="mc-CR71" publication-type="journal">Wu, C. et al. Galectin-9-CD44 interaction enhances stability and function of adaptive regulatory T cells. <italic toggle="yes">Immunity</italic><bold>41</bold>, 270&#8211;282 (2014).<pub-id pub-id-type="pmid">25065622</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.immuni.2014.06.011</pub-id><pub-id pub-id-type="pmcid">PMC4219323</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR72"><label>72.</label><citation-alternatives><element-citation id="ec-CR72" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Irie</surname><given-names>A</given-names></name><etal/></person-group><article-title>Galectin-9 as a prognostic factor with antimetastatic potential in breast cancer</article-title><source>Clin. Cancer Res.</source><year>2005</year><volume>11</volume><fpage>2962</fpage><lpage>2968</lpage><pub-id pub-id-type="pmid">15837748</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1078-0432.CCR-04-0861</pub-id></element-citation><mixed-citation id="mc-CR72" publication-type="journal">Irie, A. et al. Galectin-9 as a prognostic factor with antimetastatic potential in breast cancer. <italic toggle="yes">Clin. Cancer Res.</italic><bold>11</bold>, 2962&#8211;2968 (2005).<pub-id pub-id-type="pmid">15837748</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1078-0432.CCR-04-0861</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR73"><label>73.</label><citation-alternatives><element-citation id="ec-CR73" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yamauchi</surname><given-names>A</given-names></name><etal/></person-group><article-title>Galectin-9, a novel prognostic factor with antimetastatic potential in breast cancer</article-title><source>Breast J.</source><year>2006</year><volume>12</volume><fpage>S196</fpage><lpage>S200</lpage><pub-id pub-id-type="pmid">16959001</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1075-122X.2006.00334.x</pub-id></element-citation><mixed-citation id="mc-CR73" publication-type="journal">Yamauchi, A. et al. Galectin-9, a novel prognostic factor with antimetastatic potential in breast cancer. <italic toggle="yes">Breast J.</italic><bold>12</bold>, S196&#8211;S200 (2006).<pub-id pub-id-type="pmid">16959001</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1075-122X.2006.00334.x</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>